



YEDİTEPE UNIVERSITY

YEDİTEPE UNIVERSITY

FACULTY OF MEDICINE

PHASE III

ACADEMIC PROGRAM BOOK

2013 - 2014

YEDİTEPE UNIVERSITY

FACULTY of MEDICINE

PHASE III

ACADEMIC PROGRAM BOOK

2013 – 2014

Student's :

Name:.....

Number:.....

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

CONTENTS	Page
AIMS AND OUTCOMES OF MEDICAL EDUCATION PROGRAM.....	1
PHASE III COORDINATION COMMITTEE.....	5
DESCRIPTION OF THE PHASE	6
PHASE CONTENT	6
EXECUTIVES OF ACADEMIC YEAR	6
AIMS AND OBJECTIVES OF PHASE III.....	7
ACADEMIC CALENDAR 2013 - 2014.....	10
STUDENT COUNSELING.....	12
LIST OF STUDENT COUNSELING.....	13
ASSESSMENTS OF PHASE III.....	15
COMMITTEE I INFECTIOUS DISEASES.....	17
COMMITTEE II CARDIOLOGY AND RESPIRATORY SYSTEM.....	27
COMMITTEE III HEMATOPOIETIC SYSTEM.....	39
COMMITTEE IV GASTROINTESTINAL SYSTEM.....	47
COMMITTEE V ENDOCRINE SYSTEM & REPRODUCTIVE SYSTEM.....	56
COMMITTEE VI URINARY SYSTEM	65
COMMITTEE VII NERVOUS SYSTEM & PSYCHIATRY.....	74
COMMITTEE VIII MUSCULOSKELETAL SYSTEM.....	85
CONTACT INFORMATION.....	94

YEDİTEPE UNIVERSITY FACULTY OF MEDICINE
AIM AND OUTCOMES OF MEDICAL EDUCATION PROGRAM^{*,}**

***“Consensus Commission Report” based on draft compiled at “Workshop for Revision of
Aim and Outcomes of Medical Education Program at Yeditepe University Faculty of
Medicine”**

****© 2011, Yeditepe University Faculty of Medicine**

AIMS

The aim of medical education program ***is to graduate physicians*** who

- ***are aware of*** the local and global health issues
- ***have acquired competence*** in knowledge, skills and attitudes to manage and provide primary health care service
- ***know, apply and care*** for ethical principles of the medical profession
- ***keep up with*** current knowledge at national and international level
- ***are capable of*** systematical thinking
- ***are*** investigative and questioning
- continually ***renovate*** and ***improve*** themselves
- ***are capable of*** teamwork
- ***use*** technology competently in medicine and related areas
- ***have*** effective communication skills
- ***have*** community leadership qualifications

OUTCOMES

Graduate should be able to:

1) *practice* as a physician,

- **oriented towards**
 - **individual and non-individual factors affecting health**
 - **sustainment and improvement of healthy condition**
 - **clinical conditions which**
 - **are frequent in community**

and/or

 - **pose high risk for individual or community health**
 - **life-threatening or constitute an emergency**
- **at a competency level appropriate to deliver primary health care services compatible with surrounding context of health determinants.**

- 1.1. **explain** normal structural components of human body, their functions and operational mechanisms at organismal, multisystem, system, organ, tissue, cellular and molecular levels.
- 1.2. **explain** healthy condition and factors affecting health.
- 1.3. **explain** and **relates** causes of clinical conditions, courses of effect and outcomes.
- 1.4. **explain** changes (*i.e. physiological and pathological*) in structural components of body, their functions and operational mechanisms under healthy and clinical conditions.
- 1.5. **explain** most frequently occurring or most important clinical complaints (*i.e. chief complaint*), symptoms, signs, laboratory and imaging findings and their emergence mechanisms in clinical conditions.
- 1.6. **explain** current medical and surgical methods used in interventions directed towards health conditions.
- 1.7. **use** contextually appropriate medical history taking method, out of different types (*e.g. comprehensive, focused or hypothetico-deductive*) and systematically, to gather medical information from healthy individual, patient or patient's companions (*i.e. heteroanamnesis*), in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.
- 1.8. **employ** physical examination methods for systems in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.
- 1.9. accurately **interpret** findings in medical history and physical examination, in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.
- 1.10. **implement** diagnostic procedures (*e.g. point of care testing, physician office testing*) required for primary health care, in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.
- 1.11. **select (utilize)** tests shown to be highly effective in clinical decision making by evidence-based medicine from the aspects of reliability, practicality and outcome measures, in case of an encounter with a healthy person or a patient who seeks health care service for a health condition, and **interpret** results.
- 1.12. **make** clinical decisions (*e.g. benefit estimation, risk estimation, prevention, screening, test requisition, diagnosis, triage, staging, consultation, prognosis, watchful-waiting, intervention, monitoring, end of intervention, discharge, control, end of follow-up*) shown to be highly effective from the aspects of outcome measures by evidence-based medicine, in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.
- 1.13. accurately **perform** interventional procedures (*i.e. interventional clinical skills, competencies and proficiencies*) required for primary health care, in case of an encounter with a healthy person or a patient who seeks health care service for a clinical condition.
- 1.14. **coordinate** referral or transport of patient, when necessary and with patient-centered approach, to secondary health care institution, without posing any risk to patient's health,

security and confidentiality, in case of an encounter with a patient who seeks health care service for a clinical condition.

- 1.15. **manage** request or symptom, healthy or clinical condition, and healthy individual or patient, with beneficiary-centered approach, and with clinical decisions made by analytical and critical thinking, clinical reasoning and problem solving methods, in case of an encounter with a patient who seeks health care service for a health condition.
- 1.16. **execute** protective and therapeutic medical practices that are individual, family and community-oriented, easily accessible, integrated and coordinated, continuous, comprehensive, and based on the principles of confidentiality, in primary health care services.
- 1.17. **identify** factors that pose a high risk to individual and community health, and **determine** individuals or populations at risk in advance or at an early stage and implement the necessary measures.
- 1.18. **value** preventive health services, **offer** primary prevention (*i.e. prevention of diseases for the protection of health*), secondary prevention (*i.e. early diagnosis and treatment*) and tertiary prevention (*i.e. rehabilitation*) services, and **provide** consultancy on these issues.
- 1.19. **provide** life-style consultancy and design services to sustain and improve individual and community health.

2) **manage primary health care services.**

- 2.1. **manage** health care team in primary health care organization.
- 2.2. **lead** community with sense of responsibility, good behavior and manners in consideration of individual behaviors and social dynamics of community, and if there is a necessity, **develop** projects directed towards health care services.
- 2.3. **define** health management and economics principles, models for organization and finance of health care services.
- 2.4. **use** health care resources with cost-effective manners.

3) **advocate individual and community health under all circumstances.**

- 3.1. **provide** consultancy services to sustain and promote the health of individual and community.
- 3.2. **explain** epidemiology of clinical conditions, and **define** measures to reduce frequencies.
- 3.3. **describe** completely all high risk factors for the community health (*e.g. natural disasters, nuclear accidents, fire, war, bio-terrorism, etc.*), and **implement** necessary measures in order to prevent effects on health.
- 3.4. **explain** health determinants completely (*e.g. physical environment, social environment, genetic background, individual response -behavior, biology-, health care services, welfare, etc.*), including conditions that prevent access to health care.

4) **perform medical practices according to regulatory and ethical principles and in consideration of behavioral sciences, social sciences, and humanities.**

- 4.1. **recognize** determinants affecting individual behaviors and attitudes, and social dynamics.
- 4.2. **recognize** basic ethical principles completely, and **distinguish** ethical and legal problems.
- 4.3. **recognize** regulations concerning national and international health systems.
- 4.4. **employ** safety, security and confidentiality principles completely for beneficiaries of health care services, companions and visitors, and health care workers.
- 4.5. **use** medical record and information systems according to regulations and ethical principles.
- 4.6. **value** informed consent taking in the framework of patients' rights, and **employ** fully.
- 4.7. **interpret** historical, anthropological and philosophical evolution of medicine, health and disease concepts, and **relate** to current medical practice.

5) **establish correct and effective communication with all stakeholders of health care services and collaborate.**

- 5.1. **communicate** by using problem solving abilities during all of professional life with health care beneficiaries, co-workers, accompanying persons, visitors, patient's relatives, care givers, colleagues, other individuals and organizations.

- 5.2. **collaborate** with related organizations and institutions, with other professionals and health care workers as a team member through using problem solving abilities.
- 5.3. **communicate** with all stakeholders with consideration of socio-cultural differences.

6) promote self medical knowledge and skills in view of the current scientific developments throughout own career.

- 6.1. **adopt** and **implement** the importance of lifelong self-learning.
- 6.2. **recognize** importance of updating knowledge and skills; **search** current advancements and improve own knowledge and skills.
- 6.3. **speak** at least one foreign language at advanced level to follow the international literature and communicate with colleagues.
- 6.4. **recognize** methods to reach current scientific knowledge, and **use** available technology.
- 6.5. **recognize** principles of evidence-based medicine, and **implement** in health care services.
- 6.6. **develop** and **present** research projects.

7) manage own postgraduate career.

- 7.1. **recognize** and **investigate** postgraduate work domains and job opportunities.
- 7.2. **determine** postgraduate work domains, job opportunities and requirements for application, **distinguish** and **plan** requirements for further training and work experience.
- 7.3. **prepare** a resume, and **recognize** job interview methods.
- 7.4. **recognize** health technologies expected to be implemented in near future and emerging work areas.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

COORDINATION COMMITTEE
(TEACHING YEAR 2013 – 2014)

Yeşim GÜROL, MD, Assoc. Prof. (Coordinator)

İ. Çağatay ACUNER, MD, Assist. Prof. (Co-coordinator)

Ayşegül ÇINAR KUŞKUCU, MD, PhD, Assist. Prof. (Co-coordinator)

Olca ÖZVEREN, MD, Assist. Prof (Co-coordinator, Committee II)

Ümit AKYÜZ, MD, Assoc. Prof (Co-coordinator, Committee IV)

Oluş API, MD, Assoc. Prof (Co-coordinator, Committee V)

Hakan KOYUNCU, MD, Assist. Prof (Co-coordinator, Committee VI)

Oğuzhan ZAHMACIOĞLU, MD, Assist. Prof (Co-coordinator, Committee VII)

Müge BIÇAKÇIGİL, MD, Assoc. Prof (Co-coordinator, Committee VIII)

PHASE III ICP COORDINATOR

Özlem TANRIÖVER, MD Assist. Prof.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

DESCRIPTION OF THE PHASE

Physiopathological process and pathological process.

PHASE CONTENT

Infectious Diseases, Cardiovascular System, Respiratory System, Hematopoietic System, Gastrointestinal System, Endocrine System, Urogenital System, Nervous System, Psychiatry, Musculoskeletal System, Basic Clinical Skills, Biomedical Ethics and Deontology, Biostatistics.

EXECUTIVES OF ACADEMIC YEAR

Emergency Medicine, Family Medicine, Anesthesiology and Reanimation, Neurosurgery, Biostatistics, Biomedical Ethics and Deontology, Pediatrics, Pediatric Surgery, Pediatric Psychiatry, Endocrinology, Infectious Diseases, Immunology, Phytotherapy, Physical Therapy and Rehabilitation, Physiopathology, Gastroenterohepatology, General Surgery, Pulmonary Diseases, Thoracic Surgery, Ophthalmology, Public Health, Hematology/Oncology, Obstetrics and Gynecology, Cardiology, Otorhinolaryngology, Nephrology, Neurology, Orthopedics and Traumatology, Pathology, Psychiatry, Radiology, Rheumatology, Medical Pharmacology, Medical Genetics, Medical Microbiology, Urology.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

AIMS and LEARNING OBJECTIVES of PHASE III

AIMS OF PHASE III

In evidence based manner ;

1. **to remind** anatomy, histology and physiology of body systems,
2. **to convey** necessary knowledge, related to body systems, on prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions.
3. at multi-system level or related to a body system, for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
 - 3.1. **to convey** necessary knowledge on risk factors, etiopathogenesis, physiopathology, and pathology,
 - 3.2. **to convey** knowledge on epidemiology,
 - 3.3. **to convey** knowledge on frequently encountered clinical complaints, symptoms, signs and findings,
 - 3.4. **to convey** necessary knowledge on health care processes, clinical decision making process, clinical decisions and clinical practices, with performance measures, for managing at the level of primary health care service,
4. **to convey** knowledge on pharmacology of drugs that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
5. **to convey** knowledge on phytotherapeutic agents that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
6. **to convey** knowledge on biostatistical analysis,
7. **to convey** basic legal and ethical principles that should be followed in practice of medical profession,
8. **to equip with** basic and advanced professional and clinical (interventional or non-interventional) skills necessary for practice of medical profession.

LEARNING OBJECTIVES OF PHASE III

At the end of this phase, student should be able to:

- 1.0. **recall** anatomy, histology and physiology of body systems.
- 2.0. **list** necessities for prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions in relation to body systems.
- 3.0. **explain** risk factors and etiopathogenesis, at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
- 4.0. at cellular or tissue level,
 - 4.1. **recognize** morphological characteristics,
 - 4.2. **show** basic pathological changes that occur in clinical conditions.
- 5.0. at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
 - 5.1. **explain** mechanisms of destruction at molecule, cell, tissue, organ, system, multi-system and organismal level,
 - 5.2. **describe** structural and functional changes caused,
 - 5.3. **list** clinical courses in time.
- 6.0. **explain** mechanisms of emergence for frequently encountered;
 - 6.1. clinical complaints,
 - 6.2. symptoms,
 - 6.3. signs,
 - 6.4. laboratory and imaging findings
of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
- 7.0. at multi-system level or related to a body system,
 - for healthy conditions in an individual or community with a request, or
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and with performance measures from the aspects of reliability, practicality and outcomes,
 - health care processes,
 - acquisition of subjective or objective data, information and knowledge required for clinical decision making,
 - clinical decision making process,
 - clinical decisions and
 - clinical practiceswhich are required for management at primary health care service level.
- 7.1. practice of history taking and physical examination (*cardiovascular-C2, pulmonary-C2, gastrointestinal-C4, gynecological-C5, breast-C5, neonatal, prepubertal/pubertal-C6, neurological/neuropsychiatric-C7, musculoskeletal-C8*)
- 7.2. evaluation of emergency case (*sepsis and septic shock-C1, dyspnea-C2, acute abdominal pain-C4, urological emergencies-C6, neurological emergencies-C7, trauma-C8*)
- 7.3. approach to healthy individual or patient (*fever-C1, cardiovascular disease-C2, chest pain-C2, cough and hemoptysis-C2, dyspnea-C2, anemia-C3, lymphadenopathy-C3, diarrhea-C4, pregnancy-C5, urinary tract infection-C6, neurological symptoms-C7, headache-C7, depression-C7, dementia-C7, musculoskeletal dysfunction-C8*)
- 7.4. laboratory and imaging tests/examinations
 - 7.4.1. based on laboratory disciplines/subdisciplines;
 1. medical biochemistry tests:
 - i. (*venous blood collection-C5*)
 - ii. (*thyroid function tests-C5, diabetes tests-C5*)
 2. medical microbiology tests:
 - i. (*urine sample collection-C1, throat swab specimen-C5, sputum sample collection-C5, urethral-vaginal-cervical discharge/swab specimen-C6, fecal specimen collection-C6, wound sample collection-,blood collection for culture-*)

- ii. *(urine strip/dipstick test-C1, urine culture-C1, rapid screening (antigen/antibody) tests-C5, throat culture-C5, sputum culture-C5, urethral-vaginal-cervical discharge culture-C6, fecal culture-C6, wound culture-, blood culture-)*
- 3. medical pathology tests:
 - i. *(C2, C4, C6, C7, C8, Pap smear collection)*
 - ii. *(C2, C4, C6, C7, C8, Pap smear)*
- 4. other laboratory tests:
 - i. *(peripheral/venous blood collection for hematology tests-C3, blood sample collection for therapeutic drug monitoring-C8)*
 - ii. *(pulmonary function tests-C2, hematology tests for anemia-C3, monitorization of drug therapy-C8)*
- 7.4.2. imaging tests/examinations based on disciplines/subdisciplines:
 - 5. radiological examinations: *(radiological examinations in gynecology-C5, breast imaging-C5, urology-C6, conventional neuroradiological examinations-C7, spinal neuroradiology-C7, cranial CT-C7, cranial MRI-C7, radiological imaging of musculoskeletal system-C8, radiological examinations in benign ve malign tumors of bones-C8)*
 - 6. nuclear medicine examinations: *(nuclear medicine tests in infectious diseases-C1, radionuclide ventriculography-C2, myocardial scintigraphy-C2, cardiac PET-C2, ventilation/perfusion scintigraphy-C2, PET in lung cancer-C2, nuclear medicine tests in hematology-C3, scintigraphy of liver/spleen-C4, PET in gastrointestinal system tumors-C4, radioisotope imaging of thyroid and parathyroid-C5, renal scintigraphy (GFR, ERPF, Renogram)-C6, brain perfusion scintigraphy-C7, brain PET-C7, bone scintigraphy-C8)*
- 7.4.3. point of care testing
 - a. based on laboratory disciplines/subdisciplines;
 - 1. medical biochemistry tests: *(diabetes tests-C5, cardiac markers-, coagulation tests-, blood gases-).*
 - 2. medical microbiology tests: *(urine strip/dipstick test-C1, rapid screening (antigen/antibody tests-C5)*
 - 3. other laboratory tests: *(hematology-peripheral blood smear examination-C3, hematology-complete blood count-)*
- 7.5. making preliminary diagnosis or definitive diagnosis decision
- 7.6. making non-intervention or intervention decision
- 7.7. practicing non-intervention or intervention
- 7.8. referral/transport of healthy individual or patient

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

ACADEMIC CALENDAR 2013 - 2014

COMMITTEE I

INFECTIOUS DISEASES

(4 WEEKS)

Beginning of Committee	September 09, 2013	Monday
End of Committee	September 30, 2013	Monday
Committee Exam	October 04, 2013	Friday

COMMITTEE II

CARDIOLOGY AND RESPIRATORY SYSTEM

(8 WEEKS)

Beginning of Committee	October 07, 2013	Monday
End of Committee	November 22, 2013	Friday
Committee Exam	November 29, 2013	Friday

Religious Holiday	October 14, 2013	October 20, 2013
National Holiday	October 28-29, 2013	Monday-Tuesday
Commemoration of Atatürk	November 08, 2013	Friday

COMMITTEE III

HEMATOPOIETIC SYSTEM

(3 WEEKS)

Beginning of Committee	December 02, 2013	Monday
End of Committee	December 16, 2013	Monday
Committee Exam	December 20, 2013	Friday

COMMITTEE IV

GASTROINTESTINAL SYSTEM

(4 WEEKS)

Beginning of Committee	December 23, 2013	Monday
End of Committee	January 13, 2014	Monday
OSCE I (Exam)	January 14, 2014	Tuesday
Committee Exam	January 17, 2014	Friday

New Year	January 1, 2014	Tuesday
Coordination Committee Meeting	January 2, 2014	Thursday (09:00-12:00)
MIDTERM BREAK	January 17, 2014	February 02, 2014
Make-up Exam I	February 10, 2014	Monday

COMMITTEE V
ENDOCRINE SYSTEM & REPRODUCTIVE SYSTEM (4 WEEKS)

Beginning of Committee	February 03, 2014	Monday
End of Committee	February 25, 2014	Tuesday
Committee Exam	February 28, 2014	Friday

COMMITTEE VI
URINARY SYSTEM (4 WEEKS)

Beginning of Committee	March 03, 2014	Monday
End of Committee	March 24, 2014	Monday
Committee Exam	March 28, 2014	Friday

Physicians' Day **March 14, 2014** **Friday**

COMMITTEE VII
NERVOUS SYSTEM & PSYCHIATRY (6 WEEKS)

Beginning of Committee	March 31, 2014	Monday
End of Committee	May 06, 2014	Tuesday
Committee Exam	May 09, 2014	Friday

National Holiday	April 23, 2014	Wednesday
Coordination Committee Meeting	April 24, 2014	Thursday (09:00-12:00)
Labor's Day	May 1, 2014	Thursday

COMMITTEE VIII
MUSCULOSKELETAL SYSTEM (4 WEEKS)

Beginning of Committee	May 12, 2014	Monday
End of Committee	June 02, 2014	Monday
OSCE II (Exam)	June 03 , 2014	Tuesday
Committee Exam	June 06, 2014	Friday

Make-up Exam II **June 16, 2014** **Monday**

OSCE I (Exam)	January 14, 2014	Tuesday
OSCE II (Exam)	June 03, 2014	Tuesday

Final Exam	June 30, 2014	Monday
Incomplete Exam	July 25, 2014	Friday

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

STUDENT COUNSELING

Student counseling is a structured development process established between the student and the consultant that aims to maximize student success by focusing the student to her/his target. Although the major component of this relationship is the student, the faculties also take part by bringing the requirements of this interaction to their systems. The targeted outcomes of the consultant-student interaction are success in the exams, success in the program, and preparation for the professional life. The aim of counseling is to help students to solve their problems, to give professional guidance, to provide coaching, to contribute to adopting the habit of lifelong learning, to provide information about the University and Faculty, to follow their success and failure and to help them select courses.

The consultants selected among Basic Medical Sciences instructors for the first three years transfer the students to Clinical Sciences instructors for the following three years.

The topics that will be addressed by the consultants are as follows:

- a. Inform students about the university, faculty and surrounding facilities
- b. Inform students about the courses and help them select courses
- c. Inform students about the education and assessment regulations
- d. Follow students attendance to lectures and success
- e. In case of failure, investigate the causes and cooperate with the students to overcome them
- f. Help students in career planning
- g. Contribute to students adapting the habit of lifelong learning
- h. Guide students to counseling services of the university
- i. Set a role model as long as the professional susceptibility, professional guidance, intellectual responsibility, interaction with peers, ethics, professional values are concerned
- j. Contribute to cultivation of professional and intellectual development in a rapidly changing world
- k. Inform the coordinator when there are unsolved problems of the students

Consultant-student relationship is a dynamic and mutual process carried out within the campus and the hospital. It is recommended that the consultant and the student meet at least twice during a semester.

The expectations from the student are as follows:

- a) Contribute to improvement of satisfaction level in the problem areas
- b) Report the social and economic conditions that require consultant's help
- c) Specify expectations from the education and the department from which this training is taken
- d) Give feedback on the counseling services regarding their satisfaction level

LIST OF STUDENT COUNSELING

PHASE III

MUSTAFA FARAH	ABDULLAH	Dr. Ünal Uslu
ULAŞ	AKTOK	Dr. Ünal Uslu
TOLGA	AKYOL	Dr. Ünal Uslu
GÖKBERK	ALKAN	Dr. Ünal Uslu
CANDAN	ALTINDAŞ	Dr. Deniz Kırar
ANIL	ALTUNKAYA	Dr. Deniz Kırar
ECE	ARBABI	Dr. Deniz Kırar
TUĞBERK	ARSLAN	Dr. Deniz Kırar
SERKAN	ASLAN	Dr. Cigdem Kaspar
BÜŞRA SERAY	AYHAN	Dr. Cigdem Kaspar
SEDA	AYKANAT	Dr. Cigdem Kaspar
JNEV	BIROS	Dr. Cigdem Kaspar
ALP ER TUNGA	BÖLÜKBAŞI	Dr. Burcu Seker
ABDULMELİK	BUCAK	Dr. Burcu Seker
İSMAİL	CEBECİ	Dr. Burcu Seker
BİLGE	ÇINAR	Dr. Gulden Celik
DOĞAN CAN	ÇELİK	Dr. Kaan Yucel
KARTAL BUĞRA	ÇELİK	Dr. Kaan Yucel
ECEM	DEĞİRMENCİOĞLU	Dr. Akif Maharramov
ONUR CAN	DEMİR	Dr. Gulden Celik
FULYA	DEMİRCİ	Dr. Turgay İsbir
NAZLİDENİZ	DOĞAN	Dr. Turgay İsbir
AYÇA	DOĞANCAN	Dr. Turgay İsbir
ÖMER CAN	DOĞRUL	Dr. Elif Vatanoglu
TUĞÇE	EMİR	Dr. Elif Vatanoglu
MEHMET CAN	ERATA	Dr. Elif Vatanoglu
IŞIN	ERDOĞAN	Dr. Yeşim Gurol
FURKAN	ERDOĞAN	Dr. Elif Vatanoglu
GÖKÇE MELİS	GİRGİN	Dr. Yeşim Gurol
MERT	GÜNDOĞDU	Dr. Yeşim Gurol
EDİZ EMRE	GÜNDÜZ	Dr. Cagatay Acuner
EDA	GÜNER	Dr. Cagatay Acuner

AYŞE BESTE	GÜZEL	Dr. Cagatay Acuner
FEYZA PELİN	HAKSEVER	Dr. Bayram Yılmaz
ALPER	HORASAN	Dr. Bayram Yılmaz
YUSUF	KAVUZLU	Dr. Bayram Yılmaz
ÖZGE	KESKİN	Dr. Alev Cumbul
MELİS	KETENCİ	Dr. Alev Cumbul
EZGİ	KILIÇ	Dr. Alev Cumbul
ADNAN BERKAY	KISAKÜREK	Dr. Özlem Tanrıover
ŞÜKRÜCAN	KOCABAŞ	Dr. Özlem Tanrıover
MİRAY	KOÇ	Dr. Özlem Tanrıover
CANSU	KURT	Dr. Hulya Akan
MÜRÜVVE GİZEM	KUTLU	Dr. Hulya Akan
KHALED	MASOUD	Dr. Hulya Akan
ALPER YUSUF	MERCAN	Dr. İnci Özden
ADAM NUR	MOMİN	Dr. İnci Özden
RİTA	MUSLEH	Dr. İnci Özden
USAMA SULEIMAN	NASSOR	Dr. Jale Coban
MUSTAFA ARDA	ONAR	Dr. Arzu Akalın
ÖZGE ŞEYMA	ÖGE	Dr. Jale Coban
DİLARA	ÖMER	Dr. Jale Coban
MERVE	ÖZDOĞAN	Dr. Arzu Akalın
SÜLEYMAN	ÖZEN	Dr. Arzu Akalın
PELİN	ÖZKAN	Dr.Ece Genc
MELİS	ÖZYAZANLAR	Dr.Ece Genc
AYDA	PARNIANFARD	Dr.Ece Genc
MERYEM GÖKÇE	PEKER	Dr.Serdar Alpan
IRMAK	SALT	Dr.Serdar Alpan
RAMONA FETHİYE	SCHMİDT	Dr.Serdar Alpan
RAPHAEL REFİK	SCHMİDT	Dr. Ayşegül Kuskucu
HASSAN AHMED	SHIRWA	Dr. Ayşegül Kuskucu
MÜGE	SÖNMEZİŞİK	Dr. Ayşegül Kuskucu
TUĞÇE	SÖZDUYAR	Dr. Ferda Ozkan
KAAN	ŞARKAYA	Dr. Ferda Ozkan
GAYE	ŞENSÖZ	Dr. Ferda Ozkan
BEDRİYE CANSU	TALAY	Dr. Ferda Ozkan
KUTAL METE	TEKİN	Dr. İsin Dogan Ekici
SELEN	TULUNOĞLU	Dr. İsin Dogan Ekici
CANSU	TURALİOĞLU	Dr. İsin Dogan Ekici
OZAN	TUZCU	Dr. Gulderen Yanıkkaya Demirel
ÖYKÜ	ÜNSAL	Dr. Gulderen Yanıkkaya Demirel
İPEK	ÜLKERSOY	Dr. Gulderen Yanıkkaya Demirel
MERT	YAVUZ	Dr. Soner Dogan
BASİL AMAR	QZAIH	Dr. Soner Dogan

FACULTY OF MEDICINE

PHASE III

ASSESSMENTS

Assessments table will be made with consideration of each learning objective for each committee and will be announced and explained in introductory lectures at the beginning of the committee.

EXAMINATION MATRIX

MD 320 Introduction to Clinical Sciences

Assessment Modalities

- **WE: Written (Theoretical) Exams**
 - MCQ: Multiple Choice Questions.
 - EMQ: Extended Match Questions.
- **PE: Practical Exams**
 - OSCE: Objectively Structured Clinical Exam*
- **SPW: Scientific Project Writing** (Assessment by the lecturer)

*A form of performance-based testing used to measure a student's clinical competence. During an OSCE, students are observed and evaluated as they go through a series of stations in which they interview, examine and treat standardized patients who present with some type of medical problem.

Written (Theoretical) Exams (WE)

- **Committee Exams (CE)**
 - Number of Questions: 100
 - Question Types: 10% EMQ**, 90% MCQ
- **Final Exam (FE)**
 - Question Number: 200
 - Question Types: 100% MCQ
- **Incomplete Exam (IC)**
 - Question Number: 100
 - Question Type: 100% MCQ

**Percentage that will be reflected in total points of exam. Does not correspond to the exact number of questions.

Term Score (Pass or Fail) Calculation***:

- Term Score=(40% of CE Average)+(60% of Final Score or Incomplete Score)
 - Final Score=(OSCE₁ 5%)+(OSCE₂ 5%)+(SPW 4%)+(FE 86%)
 - Incomplete Score=(OSCE₁ 5%)+(OSCE₂ 5%)+(SPW 4%)+(IC 86%)

***Fail: FE<50 or Term Score<50

Pass: Term Score>50

What is OSCE?

The objective structured clinical examination (OSCE) is a proven valid and reliable, used both for formative and summative tool for assessing the clinical skills of medical students (1-3).

OSCE is a type of performance-based examination used to measure a student's clinical competence. During an OSCE, students are observed and evaluated in which they interview, examine and write prescriptions to standardized patients who present with a medical problem.

What is the infrastructure of your laboratory?

We have three examination room designed as doctors office which are monitored by 360 degrees cameras, we have an observer room with a one sided mirror and a control room equipped with computers and monitoring stations.

How is the performance evaluated?

Monitored exam rooms are used for taking a history from a standardized patient, performing a physical examination or diagnostic procedure, or teaching/counseling/advising a patient. A rating form or standardized checklist is used for the evaluation criteria.

A student is asked to answer questions, write a report or a prescription, or interpret findings such as lab reports and X-rays. The types of problems portrayed in an OSCE are those students would commonly see in a clinic or hospital. OSCE stations are mostly planned clinical encounters in which a student interacts with a standardized patient (SP). Evaluation criteria are based on course objectives and student learning activities.

References:

1. Harden RM, Gleeson FA. Assessment of clinical competence using an objective structured clinical examination (OSCE). *Med Educ* 1979;13:41–5.
2. Cohen R, Reznick RK, Taylor BR, Provan J, Rothman A. Reliability and validity of the objective structured clinical examination in assessing surgical residents. *Am J Surg*. 1990; 160:302-5.
3. Newble DI. Assessing clinical competence at the undergraduate level. *Med Educ*. 1992 ;26:504-11.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**INFECTIOUS DISEASES
COMMITTEE I**

DISTRIBUTION of LECTURE HOURS

September 09, 2013 – October 01, 2013

COMMITTEE DURATION: 4 WEEKS

DISCIPLINE	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
• INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY	IDCM	16		2 (4 Groups)		18
• PHARMACOLOGY	PC	15				15
• PATHOLOGY	PT	8				8
• PUBLIC HEALTH	PH	8				8
• BIOMEDICAL ETHICS & DEONTOLOGY	BED	8				8
• CSL	CSL			3 (4 Groups)		3
• BIOSTATISTICS	BS	2			2	4
• INTERNAL MEDICINE	IM	2				2
• PATHOPHYSIOLOGY	PP	2				2
• FAMILY MEDICINE	FM	2				2
• MEDICAL GENETICS	MG	2				2
• EMERGENCY MEDICINE	EM	1				1
• SCIENTIFIC PROJECTS-III	SPW	1				1
TOTAL		67		5	2	74

Coordination Committee

HEAD	Gülden Çelik, MD, Prof.
SECRETARY	İ. Çağatay Acuner, MD, Assoc. Prof.
MEMBER	Meral Sönmezoğlu, MD, Assoc. Prof.
MEMBER	Serdar Alpan, MD, Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**INFECTIOUS DISEASES
LECTURERS**

DISCIPLINE	LECTURERS
INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY	Gülden Çelik, MD Prof. Meral Sönmezoğlu, MD Assoc. Prof. Yeşim Gürol, MD Assoc. Prof. İ. Çağatay Acuner, MD Assoc Prof.
INTERNAL MEDICINE	Yaşar Küçükardalı, MD Prof
PHARMACOLOGY	Serdar Alban, MD PhD Prof.
PATHOLOGY	Ferda Özkan, MD Prof. Işın Doğan Ekici, MD Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Koçak, MD PhD.
PUBLIC HEALTH	Özlem Tanrıöver M.D. Assist. Prof
FAMILY MEDICINE	Güldal İzbirak, MD Assist. Prof. Özlem Tanrıöver, MD Assist. Prof.
CSL	Sezgin Sarıkaya, MD Assoc. Prof Didem Ay, MD Assoc. Prof Can Aktaş, MD Assoc. Prof Aslı Çetin, MD Assist. Prof
EMERGENCY MEDICINE	Sezgin Sarıkaya, MD Assoc. Prof. Can Aktaş, MD Assoc. Prof. Didem Ay, MD Assoc. Prof. Aslı Çetin, MD Assist. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD Assist. Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD Assist. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
SCIENTIFIC PROJECTS-III	Gülderen Yanıkkaya Demirel, MD PhD Assoc. Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**INFECTIOUS DISEASES
COMMITTEE I**

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. **to remind** knowledge on structures of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
2. **to convey** knowledge on epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
3. **to convey** knowledge on pathogenesis mechanisms of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
4. **to convey** necessary knowledge on prevention of infectious clinical conditions, and protection or improvement of health against these conditions,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing infectious clinical conditions, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. **to convey** necessary knowledge on pharmacology of drugs used in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
8. **to convey** necessary knowledge on ethical problems encountered in health care service and utilization, and on principles of solutions,
9. **to convey** biostatistical knowledge required in design of medical research,
10. **to convey** basic knowledge on phytotherapy,
11. **to convey** necessary knowledge on genetical basis of clinical conditions,
12. **to equip with** basic clinical skills, (intravenous injection on phantom model), required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

- 1.0. **explain** basic characteristics of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- 2.1. **recall** structures, and
- 2.2. **explain** mechanisms of pathogenesis of agents (bacteria, viruses, fungi, parasites, prions) that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- 3.0. **classify** infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, based on causative agents and systems,
- 4.0. **explain** mechanisms of change in structure and function at molecular, cellular, tissue, system, multi-system and organismal levels in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- 5.0. **explain** mechanisms of host immune response to and consequences in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- 6.0. **explain** epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- 7.0. **explain** requirements for prevention of infectious clinical conditions, and protection or improvement of health against these conditions, in healthy or susceptible individual or community,
- 8.0. **explain** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- 9.0. at multi-system level or related to a body system,
 - for healthy conditions in an individual or community with a request against infectious clinical conditions that pose risks,
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
 - health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:
- 9.1. practice of history taking and physical examination
- 9.2. evaluation of emergency case (sepsis and septic shock-C1)
- 9.3. approach to healthy individual or patient (fever-C1)
- 9.4. laboratory tests/examinations (urine sample collection-C1, urine strip/dipstick test-C1, urine culture-C1)
- 9.5. imaging tests/examinations (nuclear medicine tests in infectious diseases-C1)
- 9.6. point of care testing (urine strip/dipstick test-C1)
- 9.7. making preliminary diagnosis or definitive diagnosis decision
- 9.8. making non-intervention or intervention decision
- 9.9. practicing non-intervention or intervention
- 9.10. referral/transport of healthy individual or patient
- 10.1. **list** goals and principles of drug use,
- 10.2. **describe** effects,
- 10.3. **explain** mechanism of action (pharmacodynamics),
- 10.4. **list** indications, contraindications, pharmacological features, pharmacokinetic characteristics, drug-drug interactions and side effects,

- 10.5. **explain** resistance mechanisms of drugs (principles of antimicrobial chemotherapy, antibacterial, antifungal, antiviral, antiprotozoal, antimalarial, antihelmintic drugs, antiseptics and disinfectants) used in infectious clinical conditions,
- 11.0. **explain** interactions of health conditions (healthy and clinical conditions) at individual, family and community levels in relation to infectious agents, and importance of infectious agents and infectious clinical conditions from the aspect of public health,
- 12.0. **define** approaches (education, sanitation, hygiene, disinfection/antiseptics/sterilization, screening, surveillance, vaccination, prophylaxis, isolation, design/renovation) to control risks in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health,
- 14.0. **explain** hereditary immune system disorders,
- 15.0. **explain** ethical problems (violation of truthfulness, responsibilities of physician and patient, allocation of scarce resources) encountered in health care service and utilization, and principles of solutions,
- 16.0. **define** biostatistical knowledge required in design of medical research (research design, planning medical research,
- 17.0. **explain** basic knowledge on phytotherapy (basic concepts and terms, uses in modern medicine, regulations, standardization and quality control),
- 18.0. **perform** basic clinical skills, practiced on phantom models (intravenous injection-C1), required at primary health care service level.
- 15.0. **explain** ethical problems (violation of truthfulness, responsibilities of physician and patient, allocation of scarce resources) encountered in health care service and utilization, and principles of solutions,
- 16.0. **define** biostatistical knowledge required in design of medical research (research design, planning medical research,
- 17.0. **explain** basic knowledge on phytotherapy (basic concepts and terms, uses in modern medicine, regulations, standardization and quality control),
- 18.0. **perform** basic clinical skills, practiced on phantom models (intravenous injection-C1), required at primary health care service level.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

PHASE III COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES COURSE COMPONENT: COMMITTEE I INFECTIOUS DISEASES						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0, 2.0.,3.0. (4.0.-12.0.)	IDCM	Y. Gürol	3	1	0	4
1.0.,3.0. (4.0.-12.0.)	IDCM	M. Sönmezoglu	10	3	2	15
4.0.,5.0.	PT	F. Özkan	5	1	0	6
4.0.,5.0.	PT	I. D. Ekici	5	1	1	7
4.0.,5.0.,8.0.	PP	M. Koçak	3	1	1	5
6.0.,7.0.,11.0.,12.0.	PH	Ö. Tanrıöver	10	3	1	14
8.0.,9.0., 9.1.	IM	Y. Küçükardalı	3	1	1	5
9.2.	EM	A. Çetin	1	1	1	3
9.3. (6.0.-9.0.,11.0.,12.0.)	FM	Ö. Tanrıöver	1	1	1	3
9.3. (6.0.-9.0.,11.0.,12.0.)	FM	G. İzbirak	1	1	0	2
9.4.	IDCM	G. Çelik	9	2	1	12
10.0.	PC	S. Alpan	20	4	1	25
14.0.	MG	A. Ç. Kuskucu	3	1	1	5
15.0.	BED	E. Vatanoglu	11	3	1	15
16.0.	BS	Ç. Kaspar	5	1	1	7
TOTAL			90	25/200	13/100	128
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0, 2.0.,3.0. (4.0.-12.0.)	IDCM	Y. Gürol/ M. Sönmezoglu/ G. Çelik	2	-	-	2
10.0.	PC	S. Alpan	2	-	-	2
4.0.,5.0.	PT	I. D. Ekici/F. Özkan	1	-	-	1
TOTAL			5	-	-	5

PHASE III	COMMITTEE I	INFECTIOUS DISEASES	
I. WEEK			
DAY	HOUR	SUBJECT	LECTURER
09-Sep-2013	14:00-14:50	Introduction to Phase III	Y. Gürol İ.Ç. Acuner A.Ç. Kuşkucu
MONDAY	15:00-15:50	Semiology-I	Y. Küçükardalı
	16:00-16:50	Semiology-II	Y. Küçükardalı
10-Sep-2013	09.00-09.50	Diagnosis of Infectious Diseases I	G. Çelik
TUESDAY	10.00-10.50	Diagnosis of Infectious Diseases II	G. Çelik
	11.00-11.50	Introduction to Antimicrobial Chemotherapeutics	S. Alpan
	12.00-12.50		
	13.00-13.50		
	14.00-14.50	Introduction to the Course I	E. Vatanoğlu
	15.00-15.50	Introduction to the Course II	E. Vatanoğlu
11-Sep-2013	09.00-09.50	β Lactam Antibiotics I	S. Alpan
WEDNESDAY	10.00-10.50	β Lactam Antibiotics II	S. Alpan
	11.00-11.50	Deception and Nondisclosure I	E. Vatanoğlu
	12.00-12.50	Deception and Nondisclosure II	E. Vatanoğlu
	13.00-13.50		
	14.00-14.50	Independent study hours	
	15.00-15.50		
12-Sep-2013	09.00-09.50	The Definitions Used in the Epidemiology of Infectious Diseases	Ö. Tanrıöver
THURSDAY	10.00-10.50	Infection Prevention at Health Care Facilities and Waste Disposal	Ö. Tanrıöver
	11.00-11.50	Mortality and Morbidity Indices Used in the Epidemiology of Infectious Diseases	Ö. Tanrıöver
	12.00-12.50	Screening Tests Used in the Epidemiology of Infectious Diseases	Ö. Tanrıöver
	13.00-13.50		
	14.00-14.50	Vancomycin & Other Antimicrobial Drugs	S. Alpan
	15.00-15.50	Macrolids	S. Alpan
	16.00-16.50	Scientific Project - III: Project Writing	G. Y. Demirel
13-Sep-2013	09.00-09.50	Tissue Response to Infections	I. D. Ekici
FRIDAY	10.00-10.50	Pathology of Mycobacterial Infections	I. D. Ekici
	11.00-11.50	Tuberculosis & Other Mycobacterial Infections I	İ.Ç. Acuner
	12.00-12.50	Tuberculosis & Other Mycobacterial Infections II	M. Sönmezoğlu
	13.00-13.50		
	14.00-14.50	Independent study hours	
	15.00-15.50		

II. WEEK			
DAY	HOUR	SUBJECT	LECTURER
16-Sep-2013	09.00-09.50	Pathophysiology of Infectious Diseases I	M. Koçak
MONDAY	10.00-10.50	Pathophysiology of Infectious Diseases II	M. Koçak
	11.00-11.50	Duties of Physician and Patients I	E. Vatanoğlu
	12.00-12.50	Duties of Physician and Patients II	E. Vatanoğlu
	13.00-13.50		
	14.00-14.50	Epidemiology of Diseases Transmitted from Animals to Humans	Ö. Tanrıöver
	15.00-15.50	Epidemiology of Diseases Spread by Arthropod Vectors	Ö. Tanrıöver
	16.00-16.50	Immunization in the World and in Turkey	Ö. Tanrıöver
	17.00-17.50	Epidemiology of Diseases Spread by Food and Water	Ö. Tanrıöver
17-Sep-2013	09.00-09.50	Pathology of the Parasitic Infections	F. Özkan
TUESDAY	10.00-10.50	Parasitic Infections I	Y. Gürol
	11.00-11.50	Fungal and parasitic skin and soft tissue infections	Y. Gürol
	12.00-12.50	Pathology of Fungal Infections	F. Özkan
	13.00-13.50		
	14.00-14.50	Introduction of Medical Genetics	A. Ç. Kuşkucu
	15.00-15.50	Inherited Immun System Disorders	A. Ç. Kuşkucu
	16.00-16.50	Independent study hours	
	17.00-17.50		
18-Sep-2013	09.00-09.50	Pathology of Mycobacterial Infections	F. Özkan
WEDNESDAY	10.00-10.50	Pathology of Bacterial Infections	F. Özkan
	11.00-11.50	Antimycobacterial Drugs	S. Alpan
	12.00-12.50	Quinolones	S. Alpan
	13.00-13.50		
	14.00-14.50	Independent study hours	
	15.00-15.50		
	16.00-16.50		
	17.00-17.50		
19-Sep-2013	09.00-09.50	Bacterial and Viral Skin & Soft Tissue Infections	M. Sönmezoğlu
THURSDAY	10.00-10.50	Zoonotic Diseases I	M. Sönmezoğlu
	11.00-11.50	Zoonotic Diseases II	M. Sönmezoğlu
	12.00-12.50	Parasitic infections II	M. Sönmezoğlu
	13.00-13.50		
	14.00-14.50	Antifungal Drugs	S. Alpan
	15.00-15.50	Antiprotozoal Drugs	S. Alpan
	16.00-16.50	Independent study hours	
	17.00-17.50		
20-Sep-2013	09.00-09.50	Antimalarial Drugs	S. Alpan
FRIDAY	10.00-10.50	Antiviral Drugs	S. Alpan
	11.00-11.50	Hospital Infection	M. Sönmezoğlu
	12.00-12.50	Febril Neutropenia	M. Sönmezoğlu
	13.00-13.50		
	14.00-14.50	Independent study hours	
	15.00-15.50		
	16.00-16.50		
	17.00-17.50		

III. WEEK			
DAY	HOURL	SUBJECT	LECTURER
23-Sep-2013	09.00-09.50	Aminoglycosides	S. Alpan
MONDAY	10.00-10.50	Sulfonamides, Chloramphenicol & Tetracyclines	S. Alpan
	11.00-11.50	Pathology of Viral Infections I	I. D. Ekici
	12.00-12.50	Pathology of Viral Infections II	I. D. Ekici
	13.00-13.50		
	14.00-14.50	CSL Group I (Intravenous Injection & IV Cannulation)	C. Aktaş / D. Ay
	15.00-15.50		
	16.00-16.50		
24-Sep-2013	09.00-09.50	Infections in Immunocompromised Host	G. Çelik
TUESDAY	10.00-10.50	Vaccines	G. Çelik
	11.00-11.50	Introduction to the Program of Family Medicine	G. İzbirak
	12.00-12.50	Approach to the Patient with Fever in Primary Care	Ö. Tanrıöver
	13.00-13.50		
	14.00-14.50	Research Design	Ç. Kaspar
	15.00-15.50	Research Design	Ç. Kaspar
25-Sep-2013	09.00-09.50	Antihelmintic Drugs	S. Alpan
WEDNESDAY	10.00-10.50	Antiseptics and Disinfectants	S. Alpan
	11.00-11.50	Occupational Health Hazards I	G. Çelik
	12.00-12.50	Occupational Health Hazards II	G. Çelik
	13.00-13.50		
	14.00-14.50	CSL Group II (Intravenous Injection & IV Cannulation)	C. Aktaş / D. Ay
	15.00-15.50		
	16.00-16.50		
26-Sep-2013	09.00-09.50	Planning Medical Studies	Ç. Kaspar
THURSDAY	10.00-10.50	Planning Medical Studies	Ç. Kaspar
	11.00-11.50	Independent study hours	
	12.00-12.50		
	13.00-13.50		
	14.00-14.50	CSL Group III (Intravenous Injection & IV Cannulation)	A. Çetin
	15.00-15.50		
	16.00-16.50		
27-Sep-2013	09.00-09.50	CSL Group IV (Intravenous Injection & IV Cannulation)	A. Çetin
FRIDAY	10.00-10.50		
	11.00-11.50		
	12.00-12.50		
	13.00-13.50		
	14.00-14.50	Allocation of Scarce Resources I	E. Vatanoğlu
	15.00-15.50	Allocation of Scarce Resources II	E. Vatanoğlu
	16.00-16.50	Emergency Evaluation of Sepsis and Septic Shock	A. Çetin
	17.00-17.50	Independent study hours	

IV. WEEK			
DAY	HOURL	SUBJECT	LECTURER
30-Sep-2013	09.00-09.50	Microbiology Laboratory Techniques and Diagnostic Tests Group I	İ.Ç. Acuner
MONDAY	10.00-10.50		
	11.00-11.50	Microbiology Laboratory Techniques and Diagnostic Tests Group II	
	12.00-12.50		
	13.00-13.50	Independent study hours	
	14.00-14.50		
	15.00-15.50		
	16.00-16.50		
01-Oct--2013	09.00-09.50	Microbiology Laboratory Techniques and Diagnostic Tests Group III	İ.Ç. Acuner
TUESDAY	10.00-10.50		
	11.00-11.50	Microbiology Laboratory Techniques and Diagnostic Tests Group IV	
	12.00-12.50		
	13.00-13.50	Independent study hours	
	14.00-14.50		
	15.00-15.50		
02-03 Oct-2013	09.00-09.50	Independent study hours	
WEDNESDAY	10.00-10.50		
	11.00-11.50		
	12.00-12.50		
	13.00-13.50		
	14.00-14.50		
	15.00-15.50		
	16.00-16.50		
04-Oct-2013	10.00-13.00	COMMITTEE EXAM	
FRIDAY			

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**CARDIOVASCULAR & RESPIRATORY SYSTEMS
COMMITTEE II
DISTRIBUTION of LECTURE HOURS
October 7, 2013 – November 22 , 2013
COMMITTEE DURATION: 8 WEEKS**

DISCIPLINE	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
• PHARMACOLOGY	PC	25				25
• PATHOLOGY	PT	24	1x3=3 (2 Groups)			27
• CHEST MEDICINE	CHM	18			1x1=1	19
• CARDIOLOGY	CRD	13				13
• PUBLIC HEALTH	PH	9				9
• BIOMEDICAL ETHICS & DEONTOLOGY	BED	9				9
• PATHOPHYSIOLOGY	PP	6				6
• INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	5				5
• ENT DISEASES	ENT	4				4
• THORACIC SURGERY	TS	3				3
• FAMILY MEDICINE	FM	3				3
• MEDICAL GENETICS	MG	2				2
• BIOSTATISTICS	BS	2			1x2=2	4
• PEDIATRICS	PED	1				1
• RADIOLOGY	RAD	1				1
• EMERGENCY MEDICINE	EM	1				1
• SCIENTIFIC PROJECTS-III	SPW	1				1
• CSL	CSL			2x3=6 (4 Groups)		6
TOTAL		127	3	6	3	139

Coordination Committee

HEAD	Sevda Özdoğan, MD Prof.
SECRETARY	Olca Özveren, MD Assist. Prof.
MEMBER	Elif Eroğlu, MD Assoc. Prof.
MEMBER	Ferda Özkan, MD Prof.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
CARDIOVASCULAR & RESPIRATORY SYSTEMS
COMMITTEE II
LECTURERS

DISCIPLINE	LECTURERS
CARDIOLOGY	Muzaffer Değertekin, MD Prof. Elif Eroğlu, MD Assoc. Prof. Olca Özveren, MD Assist. Prof. Zekeriya Küçükdemir, MD Assist. Prof.
CHEST MEDICINE	Emine Sevdâ Özdoğan, MD Prof.
THORACIC SURGERY	Sina Ercan, MD Prof.
PATHOLOGY	Ferda Özkan, MD Prof. Işın Doğan Ekici, MD Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Koçak, MD PhD.
PHARMACOLOGY	Serdar Alpan, MD PhD Prof. Ece Genç, PhD Prof.
PUBLIC HEALTH	Selma Karabey, MD Prof. Yeşim Yasin
FAMILY MEDICINE	Güldal İzbirak, MD Assist. Prof. Özlem Tanrıöver, MD Assist. Prof.
PEDIATRICS	Defne Çöl, MD Ayça Vitrinel, MD, Prof.
CSL	Elif Eroğlu, MD Assoc. Prof. Olca Özveren, MD Assist. Prof. Ferdi Menda, MD Assoc. Prof.
RADIOLOGY	Neslihan Tasdelen, MD Assoc. Prof.
EAR- NOSE -THROAT (ENT)	Yavuz Selim Pata, MD Prof Müzeyyen Doğan, MD Assist. Prof
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Gülden Çelik, MD Prof. Meral Sönmezoğlu, MD Assoc. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkuç, MD PhD Assist. Prof
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD Assist. Prof
EMERGENCY MEDICINE	Didem Ay, MD Assoc. Prof
BIOSTATISTICS	Çiğdem Kaspar, PhD Assist. Prof
SCIENTIFIC PROJECTS- III	Gülderen Yanıkkaya Demirel, MD PhD Assoc. Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**CARDIOVASCULAR and RESPIRATORY SYSTEMS
COMMITTEE II**

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. **to remind** knowledge on anatomy, histology and physiology of cardiovascular and respiratory systems,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to cardiovascular and respiratory systems,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
6. **to convey** necessary knowledge together **with performance measures** on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to cardiovascular and respiratory systems, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, **at the level of primary health care service,**
7. **to convey** knowledge on principles of prescription,
8. **to convey** necessary knowledge on pharmacology of drugs effective on cardiovascular system,
9. **to convey** necessary knowledge on radiation physics and biology and its use in oncology,
10. **to convey** necessary knowledge on ethical problems encountered in health care service and utilization, and on principles of solutions,
11. **to convey** knowledge on principles of biostatistical analysis,
12. **to convey** knowledge on use of phytotherapy in an evidence based manner and drug interactions in phytotherapy,
13. **to equip with basic and advanced clinical skills** (advanced cardiac life support-C2, approach to patient with cardiovascular clinical condition-C2) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1. **recall** anatomy, histology and physiology of cardiovascular and respiratory systems,
2. **explain** etiopathogenesis of clinical conditions (*upper respiratory tract problems -nasal obstruction, etc.-, infectious clinical conditions with upper and lower respiratory tract and lung involvement - pneumonia, tuberculosis, etc.-, circulatory lung disorders -pulmonary embolism, etc.-, obstructive/restrictive lung diseases, respiratory insufficiency, tobacco use, lung tumors, other lung diseases; diseases of coronary circulation and coronary arteries, diseases of cardiac valves, myocardial and pericardial diseases, blood stream infections and sepsis, cardiac problems in adults and children, mediastinal diseases, nasopharyngeal and oropharyngeal diseases, nasal and paranasal sinus diseases, diseases of middle ear and eustachian tube, laryngeal diseases, voice disorders*) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
4. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to cardiovascular and respiratory systems,
5. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
6. at multi-system level and/or related to cardiovascular and respiratory systems,
 - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes, health care processes, clinical decision making process, clinical decisions and clinical practices
 - which are required for management at primary health care service level:
- 6.1. practice of history taking and physical examination (cardiovascular-C2, pulmonary-C2)
- 6.2. evaluation of emergency case (dyspnea-C2)
- 6.3. approach to healthy individual or patient (cardiovascular disease-C2, chest pain-C2, cough and hemoptysis-C2, dyspnea-C2)
- 6.4. laboratory tests/examinations (cardiac markers-, coagulation tests-, blood gases-, pulmonary function tests-C2)
- 6.5. imaging tests/examinations (radionuclide ventriculography-C2, myocardial scintigraphy-C2, cardiac PET-C2, ventilation/perfusion scintigraphy-C2, PET in lung cancer-C2)
- 6.6. point of care testing (urine strip/dipstick test-C1)
- 6.7. making preliminary diagnosis or definitive diagnosis decision
- 6.8. making non-intervention or intervention decision
- 6.9. practicing non-intervention or intervention
- 6.10. referral/transport of healthy individual or patient
7. **define** radiation physics, biology and its use in oncology,
8. **explain** principles of prescription,
9. **explain** pharmacology of drugs effective on cardiovascular system (autonomic system pharmacology, renin-angiotensin system pharmacology, calcium channel blockers, pharmacological approach to ischemic and congestive cardiovascular conditions, drugs effecting body fluids and volume, anti-hypertension drugs, hypolipidemic drugs, antiarrhythmic drugs,

- antiplatelet, antithrombotic and thrombolytic drugs, bronchodilator drugs, antitussive, expectorant and surfactant drugs),
10. **explain** ethical problems (rejection of treatment, organ transplantation, paternalism, reproductive and negative rights),
11. **explain** principles of biostatistical analysis,
12. **explain** use of phytotherapy in an evidence based manner, and drug interactions in phytotherapy,
13. **perform** basic clinical skills, practiced on phantom models (advanced cardiac life support-C2), and advanced clinical skills, practiced on simulated/standardized patients (approach to patient with cardiovascular clinical condition-C2), required at primary health care service.

PHASE III COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES COURSE COMPONENT: COMMITTEE II CARDIOVASCULAR & RESPIRATORY SYSTEMS						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0.,2.0.	PT	F. Özkan	9	2	1	12
1.0.,2.0.	PT	I.D. Ekici	10	3	2	15
1.0.,2.0.,5.0.,6.0.	ENT	M. Dogan	1	0	0	1
1.0.,2.0.,5.0.,6.0.	ENT	Y. S. Pata	1	0	0	1
1.0.,2.0.,5.0.,6.0.	PED	D. Çöl/A. Vitrinel	1	0	1	2
1.0.,2.0.,5.0.,6.0.	TS	S. Ercan	2	1	1	4
1.0.,2.0.,5.0.,6.0.6.4.	CRD	M.Degertekin	1	0	0	1
1.0.,2.0., 5.0., 6.0.6.1.,6.3.	CRD	Z.Küçükdemir	2	1	1	4
1.0.,2.0.,5.0.,6.0.6.4.	CRD	O. Özveren	3	0	1	4
1.0.,2.0., 5.0., 6.0.6.1.,6.3.	CRD	E. Eroglu	2	1	0	3
1.0.,2.0.,5.0.,6.0.,6.1.,6.4.,6.5.,6.6.	CHM	S. Özdoğan	12	4	1	17
2.0.,5.0.	MG	A.Ç. Kuskucu	1	0	0	1
2.0.,5.0.	PP	M. Koçak	4	1	1	6
2.0.,5.0.,6.0.	IDCM	M. Sönmezoglu	2	1	0	3
2.0.,5.0.,6.4.	IDCM	G Çelik	1	0	0	1
3.0.,4.0.	PH	S.Karabey	3	1	0	4
3.0.,4.0.	PH	Y.Yasin	4	1	1	6
6.2.	EM	D. Ay	1	0	0	1
6.3.	FM	G.Izbirak	1	0	0	1
6.3.	FM	Ö. Tanrıöver	1	0	0	1
6.5.	RAD	N. Tasdelen	1	0	0	1
8.0.,9.0.	PC	S. Alpan	13	4	1	18
9.0.	PC	E. Genç	5	1	1	7
10.0.	BED	E. Vatanoglu	7	2	1	10
11.0.	BS	Ç. Kaspar	3	1	1	5
TOTAL			90	25/200	13/100	128
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.,2.0.,5.0.,6.0.,6.1.,6.4.,6.5.,6.6.	CHM	S. Özdoğan	2	-	-	2
1.0.,2.0.,5.0.,6.0.,6.3.,6.4.	CRD	O. Özveren/ E. Eroglu	2	-	-	2
8.0.,9.0.	PC	S. Alpan/ E. Genç	1	-	-	1
TOTAL			5	-	-	5

PHASE III	COMMITTEE II	CARDIOVASCULAR and RESPIRATORY SYSTEM	
I. WEEK			
DAY	HOUR	SUBJECT	LECTURER
07-Oct-2013	09.00-09.50	Pathophysiology of Cardiovascular System Disorders I	M. Koçak
MONDAY	10.00-10.50	Pathophysiology of Cardiovascular System Disorders II	M. Koçak
	11.00-11.50	Pathophysiology of Cardiovascular System Disorders III	M. Koçak
	12.00-12.50	Independent study hours	
	13.00-13.50		
	14.00-14.50	Epidemiology and Prevention of Cardiovascular Diseases	S.Karabey
	15.00-15.50	Epidemiology of Rheumatic Fever	S.Karabey
	16.00-16.50	Epidemiology of Hypertension	S.Karabey
08-Oct-2013	09.00-09.50	Examination of the Heart	E. Eroğlu
TUESDAY	10.00-10.50	Approach to the patient with Cardiovascular System Diseases	E. Eroğlu
	11.00-11.50	General Signs and Principal Symptoms in Cardiovascular System Diseases	E. Eroğlu
	12.00-12.50	Introduction to Autonomic System Pharmacology	E. Genç
	13.00-13.50		
	14.00-14.50	Refusal of Life –saving or Life sustaining Treatment I	E. Vatanoğlu
	15.00-15.50	Refusal of Life –saving or Life sustaining Treatment II	E. Vatanoğlu
	16.00-16.50	Independent study hours	
09-Oct-2013	09.00-09.50	Electrocardiography I	Z.Küçükduymaz
WEDNESDAY	10.00-10.50	Electrocardiography II	Z.Küçükduymaz
	11.00-11.50	Preparing to analyse data	Ç.Kaspar
	12.00-12.50	Preparing to analyse data	Ç.Kaspar
	13.00-13.50		
	14.00-14.50	Acetylcholine and Directly Acting Parasympathomimetic Drugs	E. Genç
	15.00-15.50	Adrenergic Receptor Blockers	E. Genç
	16.00-16.50	Independent study hours	
10-Oct-2013	09.00-09.50	Coronary Artery Disease I	M. Değertekin
THURSDAY	10.00-10.50	Coronary Artery Disease II	M. Değertekin
	11.00-11.50	Cardiac Arrhythmias I	Z. Küçükduymaz
	12.00-12.50	Cardiac Arrhythmias II	Z. Küçükduymaz
	13.00-13.50		
	14.00-14.50	Approach to the Patient with Dyspnea in Primary Care	Ö. Tanrıöver
	15.00-15.50	End of Life decisions I	E. Vatanoğlu
	16.00-16.50	Independent study hours	
11-Oct-2013	09.00-09.50	Congestive Heart Failure	F. Özkan
FRIDAY	10.00-10.50	Congestive Heart Failure & Pericardium	F. Özkan
	11.00-11.50	Myocardium	F. Özkan

	12.00-12.50		
	13.00-13.50	Congestive Heart Failure I	E. Eroğlu
	14.00-14.50	Congestive Heart Failure II	E. Eroğlu
II. WEEK			
14-18 - Oct - 2013		RELIGIOUS HOLIDAY	
III. WEEK			
DAY	 HOUR	SUBJECT	LECTURER
21-Oct-2013	09.00-09.50	Pharmacological Approach to Congestive Heart Disease I	S. Alpan
MONDAY	10.00-10.50	Pharmacological Approach to Congestive Heart Disease II	S. Alpan
	11.00-11.50	End of Life Decisions I	E. Vatanoğlu
	12.00-12.50	End of Life Decisions II	E. Vatanoğlu
	13.00-13.50		
	14.00-14.50	Ischemic Heart Disease I	F. Özkan
	15.00-15.50	Ischemic Heart Disease II	F. Özkan
22-Oct-2013	09.00-09.50	Pathology of Endocardium & Heart Valves I	I D. Ekici
TUESDAY	10.00-10.50	Pathology of Endocardium & Heart Valves II	I D. Ekici
	11.00-11.50	Acetylcholinesterase Inhibitors	E. Genç
	12.00-12.50		
	13.00-13.50	Reproductive rights I/Negative rights	E. Vatanoğlu
	14.00-14.50	Reproductive rights II/Negative rights	E. Vatanoğlu
	15.00-15.50	Bloodstream Invasion & Sepsis I	G Çelik
	16.00-16.50	Bloodstream Invasion & Sepsis II	M. Sönmezoğlu
23-Oct-2013	09.00-09.50	Aortic Valvular Heart Diseases	O. Özveren
WEDNESDAY	10.00-10.50	Infective Endocarditis and Acute Rheumatic fever	O. Özveren
	11.00-11.50	Sympathomimetic Drugs: Catecholamines & Noncatecholamines	E. Genç
	12.00-12.50	Adrenergic Neuron Blockers	E. Genç
	13.00-13.50		
	14.00-14.50		
	15.00-15.50	Independent study hours	
	16.00-16.50		
24-Oct-2013	09.00-09.50	Cardiac Infections	M. Sönmezoğlu
THURSDAY	10.00-10.50	Atherosclerosis & Hypertension I	I D. Ekici
	11.00-11.50	Atherosclerosis & Hypertension II	I D. Ekici
	12.00-12.50	Approach to Patient with Chest Pain in Primary Care	G. İzbrak
	13.00-13.50		
	14.00-14.50		
	15.00-15.50	CSL Group IV (Advanced Cardiac Life Support)	F. Menda
	16.00-16.50		
25-Oct-2013	09.00-09.50	Mitral Valvular Heart Diseases	O. Özveren
FRIDAY	10.00-10.50	Rheumatic Heart Disease	I D. Ekici
	11.00-11.50	CVS Tumors	I D. Ekici
	12.00-12.50	Drugs Effecting Body Fluids & Volume I	S. Alpan
	13.00-13.50		

[illegible]

V. WEEK			
DAY	HOUR	SUBJECT	LECTURER
04-Nov-2013	09.00-09.50	Pathophysiology of Respiratory System Disorders I	M.Koçak
MONDAY	10.00-10.50	Pathophysiology of Respiratory System Disorders I	M.Koçak
	11.00-11.50	Pathophysiology of Respiratory System Disorders I	M.Koçak
	12.00-12.50	Bronchodilator Drugs	S. Alpan
	13.00-13.50		
	14.00-14.50	CSL Group I (Advanced Cardiac Life Support)	F. Menda
	15.00-15.50		
	16.00-16.50		
	17.00-17.50		
5-Nov-2013	09.00-09.50	Antiplatelet Drugs	S. Alpan
TUESDAY	10.00-10.50	Antithrombotic & Thrombotic Drugs	S. Alpan
	11.00-11.50	Diagnostic Methods in Pulmonary Medicine	S. Özdoğan
	12.00-12.50	Clinical Application of Pulmonary Function Tests	S. Özdoğan
	13.00-13.50		
	14.00-14.50	CSL Group II (Advanced Cardiac Life Support)	F. Menda
	15.00-15.50		
	16.00-16.50		
06-Nov-2013	09.00-09.50	Pulmonary Tuberculosis	S. Özdoğan
WEDNESDAY	10.00-10.50	Pleural Diseases	S. Özdoğan
	11.00-11.50	Pathology of Upper Respiratory Tract	F. Özkan
	12.00-12.50		
	13.00-13.50	Pulmonary Infections I	F. Özkan
	14.00-14.50	Pulmonary Infections II	F. Özkan
	15.00-15.50	Independent study hours	
	16.00-16.50		
07-Nov-2013	09.00-09.50	Lung Diseases and Tobacco	S. Özdoğan
THURSDAY	10.00-10.50	Interstitial Lung Diseases	S. Özdoğan
	11.00-11.50	X-Ray Examination of the Lungs	N.Tasdelen
	12.00-12.50	Scientific Projects- III: Project Writing	G. Y. Demirel
	13.00-13.50		
	14.00-14.50	CSL Group III (Advanced Cardiac Life Support)	F. Menda
	15.00-15.50		
	16.00-16.50		
08-Nov-2013	09.00-09.50	Independent study hours	
FRIDAY	10.00-10.50		
	11.00-11.50		
	12.00-12.50		
	13.00-13.50		
	14.00-14.50	In Commemoration of Atatürk: Rectorate Inan Kırış Conference Hall	
	15.00-15.50		

	16.00-16.50		
VI. WEEK			
DAY		SUBJECT	LECTURER
11-Nov-2013	09.00-09.50	Bronchial Hyperreactivity and Asthma	S. Özdoğan
MONDAY	10.00-10.50	Chronic Obstructive Pulmonary Disease	S. Özdoğan
	11.00-11.50	Respiratory Muscles and Surgical Anatomy of Thorax	S. Ercan
	12.00-12.50	Surgical Disorders of Mediastinum and the Diaphragm	S. Ercan
	13.00-13.50		
	14.00-14.50	Surgical Treatment of Pulmonary Diseases	S. Ercan
	15.00-15.50	Prescription Writing	S. Alpan
	16.00-16.50	Bronchodilator Drugs	S. Alpan
12-Nov-2013	09.00-09.50	Sleep Apnea Syndrome	S. Özdoğan
TUESDAY	10.00-10.50	Lung Cancer	S. Özdoğan
	11.00-11.50	Tracheobronchitis	S. Özdoğan
	12.00-12.50	Pharmacology and Toxicology of Tobacco	S. Alpan
	13.00-13.50		
	14.00-14.50	CSL GROUP III (Approach to the patient with cardiovascular disorders)	E. Eroğlu/ O. Özveren
	15.00-15.50		
	16.00-16.50		
13-Nov-2013	09.00-09.50	Pneumonia	S. Özdoğan
WEDNESDAY	10.00-10.50	Respiratory Failure	S. Özdoğan
	11.00-11.50	Principals of Statistical Analysis	Ç. Kaspar
	12.00-12.50	Principals of Statistical Analysis	Ç. Kaspar
	13.00-13.50		
	14.00-14.50	CSL GROUP IV (Approach to the patient with cardiovascular disorders)	E. Eroğlu O. Özveren
	15.00-15.50		
	16.00-16.50		
14-Nov-2013	09.00-09.50	Chronic Obstructive Pulmonary Diseases	F. Özkan
THURSDAY	10.00-10.50	Asthma Bronchiale	F. Özkan
	11.00-11.50	Congenital Lung Anomalies & Atelectasis	F. Özkan
	12.00-12.50	Emergency Evaluation of Dyspnea	D. Ay
	13.00-13.50		
	14.00-14.50	Laryngeal and Voice Diseases	M. Doğan
	15.00-15.50	Diseases of the Middle Ear and Eustachian Tube	M. Doğan
	16.00-16.50	Independent study hours	
	17.00-17.50		
15-Nov-2013	09.00-09.50	Tumors of the Respiratory System I	I.D. Ekici
FRIDAY	10.00-10.50	Tumors of the Respiratory System II	I.D. Ekici
	11.00-11.50	Pathology of Pleural and Mediastinal Diseases	I.D. Ekici
	12.00-12.50	Antitussives, Expectorants and Surfactants	S. Alpan
	13.00-13.50		
	14.00-14.50	Approach to the Patient with Cough and Hemoptysis in Primary Care	Ö. Tanrıöver

	15.00-15.50	Diseases of the Nose and Paranasal Sinuses	Y. S. Pata
	16.00-16.50	Nasopharyngeal and Oropharyngeal Diseases	Y. S. Pata
VII. WEEK			
DAY		SUBJECT	LECTURER
18-Nov-2013	09.00-09.50	Parasympatholitic Drugs	E. Genç
MONDAY	10.00-10.50	Inherited Respiratory System Disorders	A.Ç. Kuşkucu
	11.00-11.50	End of Life Decisions I	E. Vatanoğlu
	12.00-12.50	End of Life Decisions II	E. Vatanoğlu
	13.00-13.50		
	14.00-14.50	Pathology LAB I	F. Özkan/ I.D. Ekici
	15.00-15.50	Pathology LAB I	F. Özkan/ I.D. Ekici
	16.00-16.50	Pathology LAB I	F. Özkan/I.D. Ekici
19-Nov-2013	09.00-09.50	Pulmoner Hypertension	S. Özdoğan
TUESDAY	10.00-10.50	Special Pulmonary Problems	S. Özdoğan
	11.00-11.50	Pulmonary Embolism	S. Özdoğan
	12.00-12.50	CHEST MEDICINE Case Report	S. Özdoğan
	13.00-13.50		
	14.00-14.50	Pathology LAB II	F. Özkan/ I.D. Ekici
	15 00-15 50	Pathology LAB II	F. Özkan/ I.D. Ekici
	16 00-1650	Pathology LAB II	F. Özkan/ I.D. Ekici
20-Nov-2013	09.00-09.50	CSL Group II (Approach to the patient with cardiovascular disorders)	E. Eroğlu/ O. Özveren
WEDNESDAY	10.00-10.50		
	11.00-11.50		
	12.00-12.50		
	13.00-17.50	Independent study hours	
21-Nov-2013	09.00-09.50	Smoking and Related Disorders	Y.Yasin
THURSDAY	10.00-10.50	Control of Tuberculosis	Y.Yasin
	11.00-11.50	Air Pollution and Related Disorders	Y.Yasin
	12 00- 12 50	Environmental and Occupational Causes of Lung Diseases	Y.Yasin
	13.00-13.50	CSL Group I (Approach to the patient with cardiovascular disorders)	E. Eroğlu/ O. Özveren
	14.00-14.50		
	15.00-15.50		
22-Nov-2013	09.00-09.50	Upper and Lower Respiratory System Infections I	G. Çelik
FRIDAY	10.00-10.50	Upper and Lower Respiratory System Infections II	M. Sönmezoğlu
	11.00-11.50	Chronic Restrictive Pulmonary Diseases I	I D. Ekici
	12.00-12.50	Chronic Restrictive Pulmonary Diseases II	I D. Ekici
	13.00-13.50		
	14.00-14.50		
	15 00- 15 50	Independent study hours	
	16.00-16.50		

	17.00-17.50		
VIII. WEEK			
DAY	HOURL	SUBJECT	LECTURER
25-28-Nov-2013	10.00-10.50	<i>Independent study hours</i>	
	11.00-11.50		
	12.00-12.50		
	13.00-13.50		
	14.00-14.50		
	15.00-15.50		
	16.00-16.50		
	17.00-17.50		
29-Nov-2013			
FRIDAY	10.00-13.00	COMMITTEE EXAM	

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**COMMITTEE III
HEMATOPOIETIC SYSTEM
DISTRIBUTION of LECTURE HOURS**

December, 02 2013 – December, 16 2013

COMMITTEE DURATION: 3 WEEKS

• DISCIPLINE	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
• HAEMATOLOGY	HEM	17				17
• PATHOLOGY	PT	11				11
• PHARMACOLOGY	PC	8				8
• PEDIATRICS	PED	7				7
• INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	4				4
• MEDICAL GENETICS	MG	3				3
• PHYTOTHERAPY	PHY	3				3
• ONCOLOGY	ONC	2				2
• PATHOPHYSIOLOGY	PP	2				2
• BIOSTATISTICS	BS	2			1X2=2	4
• BIOMEDICAL ETHICS&DEONTOLOGY	BED	2				2
• FAMILY MEDICINE	FM	1				1
• SCIENTIFIC PROJECTS- III	SPW	1				1
• CSL	CSL			1X3=3 (4 Groups)		3
TOTAL		63		3	2	68

Coordination Committee

HEAD	Sami Kartı, MD Prof.
SECRETARY	Ayşegül Kuşkucu, MD PhD Assist. Prof.
MEMBER	Orhan Önder Eren, MD Assist Prof.
MEMBER	Işın Doğan Ekici, MD Assoc. Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**HEMATOPOIETIC SYSTEM
COMMITTEE III
LECTURERS**

DISCIPLINE	LECTURERS
HAEMATOLOGY	Sami Kartı, MD Prof.
ONCOLOGY	Orhan Önder Eren, MD Assist Prof.
PATHOLOGY	Ferda Özkan, MD Prof. A.İşin Doğan Ekici, MD Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Koçak, MD Phd
PHARMACOLOGY	Serdar Alpan, MD PhD Prof. Ece Genç, PhD Prof.
PHYTOTHERAPY	Erdem YEŞİLADA, MD PhD Prof.
PEDIATRICS	Ayça Vitrinel, MD Prof. Mehmet Reha Cengizlier, MD Prof. Filiz Bakar, MD Prof.
CSL	Sevgi Bilgen, MD Assist Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Gülden Çelik, MD Prof. Meral Sönmezoğlu, MD Assoc. Prof.
BIostatISTICS	Çiğdem KASPAR, PhD Assist. Prof.
BIOMEDICAL ETHICS&DEONTOLOGY	Elif Vatanoğlu, MD PhD Assist. Prof.
FAMILY MEDICINE	Hülya Akan, MD Assoc. Prof.
SCIENTIFIC PROJECTS - III	Gülderen Yanıkkaya Demirel, MD PhD Assoc. Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**HEMATOPOIETIC SYSTEM
COMMITTEE III**

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. **to remind** knowledge on anatomy, histology and physiology of hematopoietic system,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to hematopoietic system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. **to convey** knowledge on pharmacology of drugs that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
8. **to convey** knowledge on phytotherapeutic agents that have immune-modulatory effects,
9. **to convey** knowledge on comparative biostatistical analysis of study groups,
10. **to equip with** basic and advanced clinical skills (arterial blood sample collection-C3) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1. **recall** anatomy, histology and physiology of hematopoietic system,
2. **explain** etiopathogenesis of clinical conditions (hematological syndromes, disorders and diseases, lenforeticular infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
3. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
4. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
5. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. at multi-system level and/or related to hematopoietic system,
 - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
 - health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:
 - 6.1. practice of history taking and physical examination
 - 6.2. evaluation of emergency case
 - 6.3. approach to healthy individual or patient (anemia-C3, lymphadenopathy-C3)
 - 6.4. laboratory tests/examinations (peripheral/venous blood collection for hematology tests-C3, hematology tests for anemia-C3)
 - 6.5. imaging tests/examinations (nuclear medicine tests in hematology-C3)
 - 6.6. point of care testing (hematology-peripheral blood smear examination-C3, hematology-complete blood count-)
 - 6.7. making preliminary diagnosis or definitive diagnosis decision
 - 6.8. making non-intervention or intervention decision
 - 6.9. practicing non-intervention or intervention
 - 6.10. referral/transport of healthy individual or patient
7. **classify** blood products and blood groups,
8. **define** principles of transfusion,
9. **explain** pharmacology of drugs (antianemic drugs, antineoplastic drugs, hematostatic drugs and blood products, immunomodulators) that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
10. **explain** mechanisms of bone marrow toxicity of drugs and other chemicals,
11. **list** principles of cancer chemotherapy,
12. **explain** chemotherapy in leukemia and lymphoma,
13. **list** phytotherapeutic agents with immunomodulatory effects,
14. **list** principles of comparative biostatistical analysis of study groups,
15. **perform** basic clinical skills, practiced on phantom models (arterial blood sample collection-C3), required at primary health care service.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

PHASE III COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES COURSE COMPONENT: COMMITTEE III HEMATOPOIETIC SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER / INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0.-6.0.	HEM	S. Kartı	22	7	3	32
1.0.-6.0.	IM-ONC	O Ö.Eren	4	1	1	6
1.0.-6.0.	PED	A. Vitrinel	4	1	1	6
1.0.-6.0.	PED	M.R. Cengizlier	4	1	0	5
1.0.-6.0.	PED	F. Bakar	4	1	0	5
2.0.	MG	A. Ç. Kuskucu	4	1	1	6
2.0.,5.0.	PP	M. Koçak	2	1	0	3
2.0.,5.0.,6.4.	PT	I D. Ekici	14	4	2	20
2.0.-6.0.	IDCM	M. Sönmezoglu	5	1	1	7
2.0.-6.4.	IDCM	G. Çelik	2	1	0	3
6.3.	FM	H. Akan	1	1	0	2
9.0.-12.0.	PC	E. Genç	1	0	0	1
9.0.-12.0.	PC	S. Alpan	9	2	1	12
14.0.	BS	Ç. Kaspar	7	1	1	9
	BED	E. Vatanoglu	4	1	1	6
	PHR	E. Yesilada	3	1	1	5
TOTAL			90	25/200	13/100	128
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER / INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.-6.0.	HEM	S. Kartı	2	-	-	2
1.0.-6.0.	PED	M.R. Cengizlier	2	-	-	2
2.0.,5.0.,6.4.	PT	I D. Ekici	1	-	-	1
TOTAL			5	-	-	5

PHASE III		COMMITTEE III	HEMATOPOIETIC SYSTEM
I. WEEK			
DAY	HOURLY	SUBJECT	LECTURER
02-Dec-2013	09.00-09.50		
MONDAY	10.00-10.50	Introduction to Hematology, Signs and Symptoms in Hematological Diseases	S. Kartı
	11.00-11.50	Pathophysiology of Hematopoietic System Disorders I	M. Koçak
	12.00-12.50	Pathophysiology of Hematopoietic System Disorders II	M. Koçak
	13.00-13.50		
	14.00-14.50	Approach to the Patient with Anemia and Laboratory Tests in Diagnosis with Anemia	S.Kartı
	15.00-15.50	Hematopoiesis: Stem Cell and Bone Marrow	S. Kartı
	16.00-16.50	Aplastic and Hypoplastic Anemias	S. Kartı
03-Dec-2013	09.00-09.50	Classification of Anemias	S.Kartı
TUESDAY	10.00-10.50	Immune Acquired Hemolytic Anemias / Non Immune Acquired Hemolytic Anemias	S.Kartı
	11.00-11.50	Thalassemias and Hemoglobinopathies (Sickle Cell Anemia and Others)	S.Kartı
	12.00-12.50	Pathology of Bone Marrow-1	I D. Ekici
	13.00-13.50		
	14.00-14.50	Pathology of Bone Marrow-2	I D. Ekici
	15.00-15.50	CSL Group I (Femoral / Radial Arterial Puncture)	S. Bilgen
	16.00-16.50		
	17.00-17.50		
04-Dec-2013	09.00-09.50	Iron Metabolism and Iron Deficiency Anemia	S.Kartı
WEDNESDAY	10.00-10.50	Vitamin B ₁₂ and Folic acid Metabolism and Megaloblastic Anemias	S.Kartı
	11.00-11.50	Disorders of White Blood Cells& Leukemia I	I D. Ekici
	12.00-12.50	Disorders of White Blood Cells& Leukemia II	I D. Ekici
	13.00-13.50		
	14.00-14.50	Antianemic Drugs	E. Genç
	15.00-15.50	Molecular Basis of Hemoglobinopathies	A. Ç. Kuşucu
	16.00-16.50	Introduction to Clinical Oncology	O Ö.Eren
	17.00-17.50	Treatment Approaches of Cancer	O Ö.Eren
05-Dec-2013	09.00-09.50	Hodgkin's Lymphoma I	I D. Ekici
THURSDAY	10.00-10.50	Hodgkin's Lymphoma II	I D. Ekici
	11.00-11.50	Pharmacological Basis of Cancer Therapy	S. Alpan
	12.00-12.50		
	13.00-13.50	CSL Group II (Femoral / Radial Arterial Puncture)	S. Bilgen
	14.00-14.50		
	15.00-15.50		
06-Dec-2013	09.00-09.50	Chronic Leukemia	S. Kartı
FRIDAY	10.00-10.50	Lymphoma	S. Kartı
	11.00-11.50	Introduction to Anemias in Childhood	A. Vitrinel
	12.00-12.50	Introduction to Hemolytic Anemias	A. Vitrinel
	13.00-13.50		
	14.00-14.50	Scientific Projects- III: Project Writing	G. Yanıkkaya Demirel
	15.00-15.50	Phytotherapy-I	E.Yeşilada
	16.00-16.50	Phytotherapy-II	
	17.00-17.50	Phytotherapy-III	

II. WEEK			
DAY	HOOR	SUBJECT	LECTURER
09-Dec-2013	09.00-09.50	Acute Leukemias	S. Kartı
MONDAY	10.00-10.50	Myeloproliferative Diseases	S. Kartı
	11.00-11.50	Congenital Hemolytic Anemias I	M.R. Cengizlier
	12.00-12.50	Congenital Hemolytic Anemias II	M.R. Cengizlier
	13.00-13.50		
	14.00-14.50	CSL Group III (Femoral / Radial Arterial Puncture)	S. Bilgen
	15.00-15.50		
	16.00-16.50		
10-Dec-2013	09.00-09.50	Lenforeticular Infections I	G. Çelik
TUESDAY	10.00-10.50	Lenforeticular Infections II	M. Sönmezoğlu
	11.00-11.50	Lymphoreactive Disease	I D. Ekici
	12.00-12.50	Pathology of Spleen	I D. Ekici
	13.00-13.50		
	14.00-14.50	Genetics of Oncology I	A.Ç. Kuşkucu
	15.00-15.50	Genetics of Oncology II	A.Ç. Kuşkucu
	16.00-16.50	Independent study hours	
	17.00-17.50		
11-Dec-2013	09.00-09.50	Antineoplastic Drugs I	S. Alpan
WEDNESDAY	10.00-10.50	Antineoplastic Drugs II	S. Alpan
	11.00-11.50	Non/Hodgkin's Lymphoma I	I D. Ekici
	12.00-12.50	Non/Hodgkin's Lymphoma II	I D. Ekici
	13.00-13.50		
	14.00-14.50	Responsible Biomedical Research I	E. Vatanoğlu
	15.00-15.50	Responsible Biomedical Research II	E. Vatanoğlu
12-Dec-2013	09.00-09.50	Comparing Groups-categorical Data	Ç Kaspar
THURSDAY	10.00-10.50	Comparing Groups-categorical Data	Ç Kaspar
	11.00-11.50	Therapy of Leukomia and Lymphomas	S. Alpan
	12.00-12.50	Non/Hodgkin's Lymphoma III	I D. Ekici
	13.00-13.50		
	14.00-14.50	CSL Group IV (Femoral / Radial Arterial Puncture)	S. Bilgen
	15.00-15.50		
	16.00-16.50		
13-Dec-2013	09.00-09.50	Hemophilia and other Coagulopathies in Childhood I	F. Bakar
FRIDAY	10.00-10.50	Hemophilia and other Coagulopathies in Childhood II	F. Bakar
	11.00-11.50	Coagulation Defects	S.Kartı
	12.00-12.50	Quantitative and Qualitative Platelet Disorders	S.Kartı
	13.00-13.50		
	14.00-14.50	Comparing Groups-Continous Data	Ç. Kaspar
	15.00-15.50	Comparing Groups-Continous Data	Ç. Kaspar
	16.00-16.50	Hematostatic Drugs and Hematostatic Blood Products I	E. Genç
	17.00-17.50	Hematostatic Drugs and Hematostatic Blood Products I	E. Genç

III. WEEK			
DAY	HOUR	SUBJECT	LECTURER
16-Dec-2013 MONDAY	09.00-09.50	Blood Components and Transfusion Indications	M. Sönmezoğlu
	10.00-10.50	Blood Groups	M. Sönmezoğlu
	11.00-11.50	Hypercoagulability	S. Kartı
	12.00-12.50	Multiple Myelom	S. Kartı
	13.00-13.50		
	14.00-14.50	Bone Marrow Toxicity of Drugs and other Chemicals	S. Alpan
	15.00-15.50	Immunomodulators	S. Alpan
	16.00-16.50	Congenital Immunodeficiency Disease	M.R. Cengizlier
	17.00-17.50	Approach to the Patient with LAP	H. Akan
17-19 Dec-2013 TUESDAY	09.00-09.50	<i>Independent study hours</i>	
	10.00-10.50		
	11.00-11.50		
	12.00-12.50		
	13.00-13.50		
	14.00-14.50		
	15.00-15.50		
	16.00-16.50		
	17.00-17.50		
20-Dec-2012 FRIDAY	10.00-13.00	COMMITTEE EXAM	

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE**

PHASE III

COMMITTEE IV

GASTROINTESTINAL SYSTEM

DISTRIBUTION of LECTURE HOURS

December 23, 2014 - January 13, 2014

COMMITTEE DURATION: 4 WEEKS

• DISCIPLINE	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
• PATHOLOGY	PT	14		1x3=3 (2 Groups)		17
• GASTROENTEROHEPATOLOGY	GE	19				19
• INTERNAL MEDICINE	IM	3				3
• BIOMEDICAL ETHICS&DEONTOLOGY	BED	6				6
• PHARMACOLOGY	PC	4				4
• PUBLIC HEALTH	PH	4				4
• INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	4				4
• BIostatISTICS	BS	2			1X2=2	4
• PHYTOTHERAPY	PHY	3				3
• CSL	CSL			1X3=3 (4 Groups)		3
• PATHOPHYSIOLOGY	PP	2				2
• FAMILY MEDICINE	FM	2				2
• PEDIATRICS	PED	1				1
• PEDIATRIC SURGERY	PEDS	1				1
• RADIOLOGY	RAD	1				1
• MEDICAL GENETICS	MG	1				1
• SURGERY	GS	1				1
• EMERGENCY MEDICINE	EM	1				1
TOTAL		69		6	2	77

Coordination Committee

HEAD	Cengiz Pata, MD Prof.
SECRETARY	Ümit Akyüz, MD Assoc.. Prof.
MEMBER	Ferda Özkan, MD Prof.
MEMBER	Ece Genç, MD PhD Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**GASTROINTESTINAL SYSTEM COMMITTEE IV
LECTURERS**

DISCIPLINE	LECTURERS
GASTROENTEROHEPATOLOGY	Cengiz Pata, MD Prof. Ümit Akyüz, MD Assoc. Prof.
INTERNAL MEDICINE	Yaşar Küçükardalı, MD Prof
PATHOLOGY	Ferda Özkan, MD Prof. Işın Doğan Ekici, MD Assoc. Prof
PATHOPHYSIOLOGY	Mehtap Koçak, MD PhD
PHARMACOLOGY	Ece Genç, PhD Prof.
PEDIATRICS	Meltem Uğraş, MD Assist. Prof.
PHYTOTHERAPY	Erdem Yeşilada, MD PhD Prof
PUBLIC HEALTH	Yeşim Yasin
FAMILY MEDICINE	Hülya Akan, MD Assoc. Prof. Özlem Tanrıöver, MD Assist. Prof.
CSL	Ümit Akyüz, MD Assoc. Prof.
PEDIATRIC SURGERY	Selami Sözübir, MD Prof.
RADIOLOGY	Bengi Gürses, MD Assoc. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Meral Sömnecoğlu, MD Assoc. Prof. Yeşim Gürol, MD Assoc. Prof.
SURGERY	Özcan Gökçe, MD Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD Assist. Prof
BIOMEDICAL ETHICS&DEONTOLOGY	Elif Vatanoğlu, MD PhD Assist Prof.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

GASTROINTESTINAL SYSTEM - COMMITTEE IV

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. **to remind** knowledge on anatomy, histology and physiology of gastrointestinal system,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinal system,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to gastrointestinal system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. **to convey** knowledge on pharmacology of drugs that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
8. **to convey** knowledge on phytotherapeutic agents that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
9. **to convey** knowledge on biostatistical analysis of association between variables,
10. **to convey** necessary knowledge on legal regulations and ethical principles for end-of-life decisions,
11. **to equip with** basic and advanced clinical skills (approach to patient with gastrointestinal clinical condition-C4) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

- 1.0. **recall** anatomy, histology and physiology of gastrointestinal system,
- 2.0. **explain** etiopathogenesis of clinical conditions (infections, nutritional disorders, bleedings, clinical conditions related to gastrointestinal organs) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
- 3.0. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
- 4.0. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinal system,
- 5.0. **explain** importance of healthy nutrition, principles of balanced diet, and measurement of nutritional status,
- 6.0. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
- 7.0. at multi-system level and/or related to gastrointestinal system,
 - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
 - health care processes, clinical decision making process, clinical decisions and clinical practiceswhich are required for management at primary health care service level:
- 7.1. practice of history taking and physical examination (gastrointestinal-C4)
- 7.2. evaluation of emergency case (acute abdominal pain-C4)
- 7.3. approach to healthy individual or patient (diarrhea-C4)
- 7.4. laboratory tests/examinations
- 7.5. imaging tests/examinations (scintigraphy of liver/spleen-C4, PET in gastrointestinal system tumors-C4)
- 7.6. point of care testing
- 7.7. making preliminary diagnosis or definitive diagnosis decision
- 7.8. making non-intervention or intervention decision
- 7.9. practicing non-intervention or intervention
- 7.10. referral/transport of healthy individual or patient
8. **list** differences of gastrointestinal clinical conditions that may occur in children,
9. **explain** liver transplantation (indications, contraindications, conditions, risks, methods, patient care, results and monitorization),
10. **explain** pharmacology of drugs (agents used in the treatment of peptic ulcer, emetic and antiemetic agents, prokinetic, laxative and purgative drugs) that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
11. **explain** genetics of gastrointestinal system,
12. **explain** phytotherapeutic agents that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
13. **define** biostatistical analysis of association between variables,
14. **tell** legal regulations and ethical principles for end-of-life decisions,
15. **perform** basic clinical skills, practiced on phantom models and advanced clinical skills, practiced on simulated/standardized patients (approach to patient with gastrointestinal clinical condition-C4), required at primary health care service.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

PHASE III COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES COURSE COMPONENT: COMMITTEE IV GASTROINTESTINAL SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	GE	C. Pata	16	5	2	23
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	GE	Ü. Akyüz	9	3	1	13
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	PEDS	S. Sözübir	1	0	0	1
1.0.,2.0.,3.0.,4.0.,6.0.,6.0.,7.1.	IM	Y. Küçükardalı	3	1	1	5
2.0.,6.0.	PP	M.Koçak	2	1	1	4
2.0.,6.0.	PT	I. D. Ekici	5	1	1	7
2.0.,3.0.,4.0.,6.0.,7.0.	IDCM	M. Sönmezoglu	3	1	1	5
2.0.,3.0.,4.0.,6.0.,7.3.	EM	S. Sarıkaya	1	0	0	1
2.0.,3.0.,4.0.,6.0.,7.4.	IDCM	Y. Gürol	1	0	0	1
2.0.,3.0.,4.0.,6.0.,7.4.	IDCM	G. Çelik	1	0	0	1
2.0.,6.0.,7.4.	PT	F. Özkan	16	5	1	22
3.0.,4.0.,5.0.	PH	Y.Yasin	5	1	1	7
5.0.	PED	M. Ugras	1	0	0	1
7.3.	FM	H. Akan	1	0	0	1
7.3.	FM	Ö. Tanrıöver	1	0	0	1
7.5.	RAD	B. Gürses	1	1	0	2
9.0.	GS	Ö. Gökçe	1	0	0	1
10.0.	PC	E. Genç	5	1	1	7
11.0.	MG	A.Ç. Kuskucu	1	0	0	1
13.0.	BS	Ç. Kaspar	5	1	1	7
14.0.	BED	E. Vatanoglu	8	3	1	12
	PHR (PHY)	E. Yesilada	3	1	1	5
TOTAL			90	25/200	13/100	128
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	GE	C. Pata	3	-	-	3
2.0.,6.0.,7.4.	PT	F. Özkan	2	-	-	2
TOTAL			5	-	-	5

PHASE III		COMMITTEE IV	GASTROINTESTINAL SYSTEM
I. WEEK			
DAY	HOUR	SUBJECT	LECTURER
23-Dec-2013	09.00-09.50	Semiology	Y. Küçükardalı
MONDAY	10.00-10.50	Semiology	Y. Küçükardalı
	11.00-11.50	Pathophysiology of Gastro-intestinal Disorders I	M.Koçak
	12.00-12.50	Pathophysiology of Gastro-intestinal Disorders II	M. Koçak
	13.00-13.50		
	14.00-14.50	Oral Pathology	F. Özkan
	15.00-15.50	Pathology of Esophagus I	F. Özkan
	16.00-16.50	Pathology of Esophagus II	F. Özkan
24-Dec-2013	09.00-09.50	Acute Gastroenteritis	M. Sönmezoğlu
TUESDAY	10.00-10.50	Pathology of Stomach I	F. Özkan
	11.00-11.50	Pathology of Stomach II	F. Özkan
	12.00-12.50	Gastrointestinal Bleedings in Children	S. Sözübir
	13.00-13.50		
	14.00-14.50	Relation Between Two Variables	Ç. Kaspar
	15.00-15.50	Relation Between Two Variables	Ç. Kaspar
	16.00-16.50	Organ Transplantation and Ethics I	E. Vatanoğlu
	17.00-17.50	Organ Transplantation and Ethics II	E. Vatanoğlu
25-Dec-2013	09.00-09.50	Relation Between Several Variables	Ç. Kaspar
WEDNESDAY	10.00-10.50	Relation Between Several Variables	Ç. Kaspar
	11.00-11.50	Oral and Dental Health	
	12.00-12.50	Importance of Nutrition, Principles of Balanced Diet, Measuring Nutritional Status and Nutritional Disorders	Y.Yasin
	13.00-13.50		
	14.00-14.50	Nutritional disorders in Turkey and in the World	Y.Yasin
	15.00-15.50	Food Sanitation and Related Regulations	Y.Yasin
	16.00-16.50	Independent study hours	
	17.00-17.50		
26-Dec-2013	09.00-09.50	Jaundice	Ü.Akyüz
THURSDAY	10.00-10.50	Malabsorption	C. Pata
	11.00-11.50	Clinical Approach to the Patient with Acute Abdominal Pain	S. Sarıkaya
	12.00-12.50	Independent study hours	
	13.00-13.50		
	14.00-14.50	Pathology LAB I	F. Özkan/I.D.Ekici
	15.00-15.50	Pathology LAB I	F. Özkan/I.D.Ekici
	16.00-16.50	Pathology LAB I	F. Özkan/I.D.Ekici
27-Dec-2013	09.00-09.50	Inflammatory Bowel Disease	C. Pata
FRIDAY	10.00-10.50	Functional GI Disorders & Irritable Bowel Disease	C. Pata
	11.00-11.50	Approach to the Patient with Diarrhea Regarding to Primary Care	H. Akan
	12.00-12.50	Food Poisoning	Y. Gürol
	13.00-13.50		
	14.00-14.50	Phytotherapy-IV	E.Yeşilada
	15.00-15.50	Phytotherapy-V	
	16.00-16.50	Phytotherapy-VI	

[illegible]

III. WEEK			
DAY	HOURL	SUBJECT	LECTURER
06-Jan -2014	09.00-09.50	Malignant Lesions of the Colon	C. Pata
MONDAY	10.00-10.50	Pathology of Appendix & Peritoneum	F. Özkan
	11.00-11.50	Prokinetic, Laxative and Purgative Drugs	E. Genç
	12.00-12.50	Emetic & Antiemetic Agents	E. Genç
	13 33-13 50		
	14 00-14 50	Reproductive EthicsI	E. Vatanoğlu
	15 00-15 50	Reproductive Ethics II	E. Vatanoğlu
	16.00-16.50	Independent study hours	
	17:00-17:50		
07-Jan-2014	09.00-09.50	Otoimmun Hepatitis	Ü.Akyüz
TUESDAY	10.00-10.50	Wilson Disease and Hemochromatosis	Ü.Akyüz
	11.00-11.50	Pathology of Liver I	F. Özkan
	12.00-12.50	Pathology of Liver II	F. Özkan
	13.00-13.50		
	14.00-14.50	CSL Group IV (Approach to the patient with gastrointestinal system disorders)	Ü. Akyüz
	15.00-15.50		
	16.00-16.50		
08-Jan-2014	09.00-09.50	Chronic Viral Hepatitis	C. Pata
WEDNESDAY	10.00-10.50	Cirrhosis and Complications	C. Pata
	11.00-11.50	Drug Induced Liver Disease	C. Pata
	12.00-12.50	Mass Lesions of the Liver	C. Pata
	13.00-13.50		
	14.00-14.50	CSL GROUP III (Approach to the patient with gastrointestinal system disorders)	Ü.Akyüz
	15.00-15.50		
	16.00-16.50		
09-Jan-2014	09.00-09.50	Alcoholic and Nonalcoholic Liver Disease	Y. Küçükardalı
THURSDAY	10.00-10.50	Acute Liver Failure	Ü.Akyüz
	11.00-11.50	Pathology of Liver & Biliary System I	I. D. Ekici
	12.00-12.50	Pathology of Liver & Biliary System II	I. D. Ekici
	13.00-13.50		
	14.00-14.50	CSL Group II (Approach to the patient with gastrointestinal system disorders)	Ü.Akyüz
	15.00-15.50		
	16.00-16.50		
10-Jan-2014	09.00-09.50	Disease of the Bile Duct and Gall Bladder	Ü.Akyüz
FRIDAY	10.00-10.50	Acute and Chronic Pancreatitis	Ü.Akyüz
	11.00-11.50	Tumors of the Bile Ducts and Pancreas	Ü.Akyüz
	12.00-12.50	Pathology of Liver & Biliary System III	I.D. Ekici
	13.00-13.50		
	14.00-14.50	Pathology of Liver & Biliary System IV	I. D. Ekici
	15.00-15.50	Independent study hours	
	16.00-16.50		
	17.00-17.50		

IV. WEEK			
DAY	HOURL	SUBJECT	LECTURER
13-Jan-2014	09.00-09.50	Radiology of Gastrointestinal System I	B. Gürses
MONDAY	10.00-10.50	Transplantation of liver	Ö. Gökçe
	11.00-11.50	Inherited Gastrointestinal System Disorders	A.Ç. Kuşucu
	12.00-12.50		
	13.00-13.50	CSL GROUP I (Approach to the patient with gastrointestinal system disorders)	Ü. Akyüz
	14.00-14.50		
	15.00-15.50		
14-Jan-2014	10:00-17:50	OSCE –I EXAM	
TUESDAY			
15-16 -Jan - 2014	09.00-09.50	<i>Independent study hours</i>	
	10.00-10.50		
	11.00-11.50		
	12.00-12.50		
	13.00-13.50		
	14.00-14.50		
	15.00-15.50		
	16.00-16.50		
	17.00-17.50		
17-Jan-2014	10.00-13.00	COMMITTEE EXAM	
FRIDAY			

20 January – 02 February

MIDTERM BREAK

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM
COMMITTEE V
DISTRIBUTION of LECTURE HOURS
February 3, 2014 - March, 2014
COMMITTEE DURATION: 4 WEEKS**

• DISCIPLINE	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
• PATHOLOGY	PT	20				20
• OBST & GYN	OBS-GYN	16				16
• ENDOCRINOLOGY	END	13				13
• INTERNAL MEDICINE	IM	2				2
• PHARMACOLOGY	PC	12				12
• MEDICAL GENETICS	MG	6				6
• INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	3		1x2=2 (2 Groups)		5
• PATHOPHYSIOLOGY	PP	5				5
• BIostatISTICS	BS	2			1X2=2	4
• PUBLIC HEALTH	PH	4				4
• FAMILY MEDICINE	FM	4				4
• PEDIATRICS	PED	3				3
• CSL	CSL			1x3=3 (4 Groups)		3
• PHYTOTHERAPY	PHR (PHY)	2				2
• RADIOLOGY	RAD	1				1
• HISTOLOGY	HST	1				1
• SCIENTIFIC PROJECTS- III	SPW	1				1
TOTAL		95		5	2	102

Coordination Committee

HEAD	Cem Fıçıcıoğlu, MD Prof.
SECRETARY	Oluş Api, MD Assoc. Prof.
MEMBER	Hasan Aydın, MD Assoc. Prof.
MEMBER	Ferda Özkan, MD Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM
COMMITTEE V
LECTURERS**

DISCIPLINE	LECTURERS
OBSTETRICS and GYNECOLOGY	N. Cem Fıçıcıoğlu, MD Prof. Aslı Somunkıran, MD Assoc. Prof Oluş Api, MD Assoc. Prof. Rukset Attar, MD Assoc. Prof. Gazi Yıldırım, MD Assoc. Prof. Pınar Cenksöy, MD
ENDOCRINOLOGY	Hasan Aydın, MD Assoc. Prof.
INTERNAL MEDICINE	Yaşar Küçükardalı, MD Prof.
PATHOLOGY	Ferda Özkan, MD Prof Işın Doğan Ekici, MD Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Koçak, MD PhD
PHARMACOLOGY	Ece Genç, PhD Prof.
PEDIATRICS	Gülay Çiler Erdağ, MD Assist. Prof.
PUBLIC HEALTH	Yeşim Yasin
PHYTOTHERAPY	Erdem Yeşilada, MD PhD Prof.
FAMILY MEDICINE	Özlem Tanrıöver, MD Assist. Prof. Ayşe Arzu Akalın, MD Assist. Prof.
CSL	Aslı Somunkıran, MD Assoc. Prof Oluş Api, MD Assoc. Prof.
RADIOLOGY	Bengi Gürses, MD Assoc. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Gulden Çelik, MD Prof. Meral Sönmezoğlu, MD Assoc. Prof. Yeşim Gürol, MD Assoc. Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD Assist. Prof.
SCIENTIFIC PROJECTS- III	Gülderen Yanıkkaya Demirel, MD Assoc. Prof.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM
COMMITTEE V

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. **to remind** knowledge on anatomy, embryology, histology and physiology of endocrine and reproductive systems,
2. **to convey** knowledge on health care service practices related to reproductive care,
3. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
4. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
5. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to endocrine and reproductive systems,
6. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
7. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to endocrine and reproductive systems, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
8. **to convey** knowledge on pharmacology of drugs that are effective on endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive systems,
9. **to convey** knowledge on genetics of endocrine and reproductive systems,
10. **to convey** knowledge on phytotherapeutic agents that are effective on endocrine system or on clinical conditions involving endocrine system,
11. **to convey** knowledge on design and biostatistical analysis of survival research,
12. **to convey** knowledge on legal regulations and ethical principles related to reproductive care,
13. **to equip with** basic and advanced clinical skills (*normal spontaneous vaginal delivery on phantom model-C5*) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

- 1.0. **recall** anatomy, embryology, histology and physiology of endocrine and reproductive systems,
- 2.0. **explain** physiology of normal spontaneous vaginal delivery,
- 3.0. **define** practice of reproductive care,
- 4.0. **explain** etiopathogenesis of clinical conditions (menstrual cycle/developmental conditions/congenital and sexually transmitted infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
- 5.0. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
- 6.0. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to endocrine and reproductive systems,
- 7.0. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
- 8.0. at multi-system level and/or related to endocrine and reproductive systems,
 - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
 - health care processes, clinical decision making process, clinical decisions and clinical practiceswhich are required for management at primary health care service level:
- 8.1. practice of history taking and physical examination (gynecological-C5, breast-C5)
- 8.2. evaluation of emergency case
- 8.3. approach to healthy individual or patient (pregnancy-C5)
- 8.4. laboratory tests/examinations (venous blood collection-C5, throat swab specimen-C5, sputum sample collection-C5, thyroid function tests-C5, diabetes tests-C5, rapid screening [antigen/antibody] tests-C5, throat culture-C5, sputum culture-C5)
- 8.5. imaging tests/examinations (radiological examinations in gynecology-C5, breast imaging-C5, radioisotope imaging of thyroid and parathyroid-C5)
- 8.6. point of care testing (diabetes tests-C5, rapid screening [antigen/antibody] tests-C5)
- 8.7. making preliminary diagnosis or definitive diagnosis decision
- 8.8. making non-intervention or intervention decision
- 8.9. practicing non-intervention or intervention
- 8.10. referral/transport of healthy individual or patient
- 9.0. **explain** pharmacology of drugs (hypothalamic and pituitary hormones, drugs effecting functions and action of oxytocin and ADH, thyroid and antithyroid drugs, adrenocortical hormones and drugs, insulin and oral antidiabetic drugs, estrogens, progestines and inhibitors) that are effective on endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive systems,
- 10.0. **explain** genetics of endocrine and reproductive systems,
- 11.0. **explain** mechanisms of action for phytotherapeutic agents that are effective on endocrine system or in clinical conditions related to endocrine system,
- 12.0. **define** design and biostatistical analysis of survival research,
- 13.0. **explain** legal regulations and ethical principles related to reproductive care,
- 14.0. **perform** basic clinical skills, practiced on phantom models (normal spontaneous vaginal delivery-C5), and advanced clinical skills, practiced on simulated/standardized patients required at primary health care service.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

PHASE III COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES COURSE COMPONENT: COMMITTEE V ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0	HST	O. Akçin	1	0	0	1
1.0-8.0	OBS-GYN	C. Fıçıcıoğlu	5	2	1	8
1.0-8.0	OBS-GYN	O. Açı	3	1	0	4
1.0-8.0	OBS-GYN	R. Attar	4	1	0	5
1.0-8.0	OBS-GYN	G.Yıldırım	3	1	0	4
1.0-8.0	OBS-GYN	A.Somunkıran	2	0	1	3
1.0, 4.0-8.0	END	H. Aydın	13	3	2	18
1.0, 4.0-8.0	PED	G.Ç. Erdag	4	1	0	5
1.0, 4.0, 7.0, 8.4	PT	F. Özkan	15	3	2	20
1.0, 4.0, 7.0, 8.4	PT	I.D. Ekici	3	2	1	6
4.0, 5.0, 6.0, 7.0, 8.0	IDCM	M. Sönmezoglu	1	0	0	1
4.0, 5.0, 6.0, 7.0, 8.4	IDCM	G. Çelik	2	1	0	3
4.0, 7.0	PP	M. Koçak	4	1	1	6
5.0, 6.0	PH	Y.Yaain	3	1	1	5
6.0, 8.0,8.1, 8.3	FM	A Akalın	3	1	0	4
8.3	FM	Ö. Tanrıöver	1	0	0	1
8.5	RAD	B. Gürses	1	0	0	1
9.0	PC	E. Genç	12	3	2	17
10.0	MG	A. Ç. Kuskucu	5	2	1	8
12.0	BS	Ç. Kaspar	3	1	0	4
	PHR (PHY)	E. Yesilada	2	1	0	3
TOTAL			90	25/200	12/100	127
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0, 4.0-8.0	END	H. Aydın	2	-	-	2
1.0-8.0	OBS-GYN	R. Attar	2	-	-	2
1.0, 4.0, 7.0, 8.4	PT	F. Özkan	1	-	-	1
TOTAL			5	-	-	5

PHASE III	COMMITTEE V ENDOCRINOLOGY and REPRODUCTIVE SYSTEMS		
I. WEEK			
DAY	HOOR	SUBJECT	LECTURER
03-Feb-2014	09.00-09.50	<i>Independent study hours</i>	
MONDAY	10.00-10.50	Introduction to Endocrinology	H. Aydın
	11.00-11.50	Hyperfunctioning Disorders of Anterior Pituitary Gland	H. Aydın
	12.00-12.50	Pathology of Endocrine System: Introduction	F. Özkan
	13.00-13.50		
	14.00-14.50	Pathophysiology of Endocrine System Diseases I	M. Koçak
	15.00-15.50	Pathophysiology of Endocrine System Diseases II	M. Koçak
	16.00-16.50	Pathophysiology of Endocrine System Diseases III	M. Koçak
04-Feb-2014	09.00-09.50	Disorders of Posterior Pituitary Gland	H. Aydın
TUESDAY	10.00-10.50	Hypopituitarism	H. Aydın
	11.00-11.50	Thyroid Disorders	H. Aydın
	12.00-12.50	Hypothalamic and Pituitary Hormones	E. Genç
	13.00-13.50		
	14.00-14.50	Design of Survival Studies	Ç. Kaspar
	15.00-15.50	Design of Survival Studies	Ç. Kaspar
	16.00-16.50	<i>Independent study hours</i>	
	17.00-17.50		
05-Feb-2014	09.00-09.50	Introduction to Endocrine Pharmacology	E. Genç
WEDNESDAY	10.00-10.50	Oxytocin & ADH and Drugs Effecting their Action	E. Genç
	11.00-11.50	Thyroid Function Tests	H. Aydın
	12.00-12.50	Imaging of Thyroid Glands	B.Gürses
	13.00-13.50		
	14.00-14.50	Pathology of Thyroid & Parathyroid I	F. Özkan
	15.00-15.50	Pathology of Thyroid & Parathyroid II	F. Özkan
	16.00-16.50	Analysis of Survival Times	Ç. Kaspar
	17.00-17.50	Analysis of Survival Times	Ç. Kaspar
06-Feb-2014	09.00-09.50	Calcium Metabolism	H. Aydın
THURSDAY	10.00-10.50	Hypercalcemic Diseases	H. Aydın
	11.00-11.50	Hypocalcemic Diseases	H. Aydın
	12.00-12.50	Pathology of Adrenal Gland I	F. Özkan
	13.00-13.50		
	14.00-14.50	Pathology of Adrenal Gland II	F.Özkan
	15.00-15.50	Congenital Adrenal Hyperplasia	G.Ç. Erdağ
	16.00-16.50	Scientific Projects- III (Writing Project)	G.Y.Demirel
	17.00-17.50	<i>Independent study hours</i>	
07-Feb-2014	09.00-12.50	<i>Independent study hours</i>	
	13.00-13.50		
	14.00-14.50	Concept of Reproductive Health and How is delivered in General Health Services	Y.Yasin
	15.00-15.50	Factors affecting Maternal Mortality in	Y.Yasin

		Turkey and in the World	
	16.00-16.50	Inborn Errors of Metabolism I	A.Ç. Kuşkucu
	17.00-17.50	Inborn Errors of Metabolism II	A.Ç. Kuşkucu
II. WEEK			
DAY	HOURL	SUBJECT	LECTURER
10-Feb-2014	09.00-09.50	Introduction to Diabetes Mellitus	Y. Küçükardalı
MONDAY	10.00-10.50	Clinical and Laboratory Findings of Diabetes Mellitus	Y. Küçükardalı
	11.00-11.50	Thyroid and antithyroid drugs I	E. Genç
	12.00-12.50	Thyroid and antithyroid drugs II	E. Genç
	13.00-13.50		
	14.00-14.50	Pathology of Pituitary Gland I	I.D. Ekici
	15.00-15.50	Pathology of Pituitary Gland II	I.D. Ekici
	16.00-16.50	Phytotherapy-VII	E.Yeşilada
	17.00-17.50	Phytotherapy-VIII	
11-Feb-2014	09.00-09.50	Hypoglycemia	H. Aydın
TUESDAY	10.00-10.50	Adrenocortical Hormones and Drugs I	E. Genç
	11.00-11.50	Adrenocortical Hormones and Dugs II	E. Genç
	12.00-12.50	Pathology of Pancreas I	I.D. Ekici
	13.00-13.50		
	14.00-14.50	Pathology of Pancreas II	I.D. Ekici
	15.00-15.50	Screening Tests for Breast Cancer & Cervical Cancer	Y.Yasin
	16.00-16.50	Antenatal Care and Postnatal Care and How it is delivered	Y.Yasin
	17.00-17.50	Independent study hours	
12-Feb-2014	09.00-09.50	Adrenal Disorders	H. Aydın
WEDNESDAY	10.00-10.50	Obesity	H. Aydın
	11.00-11.50	Diffuse Hormonal Systems and Endocrine Tumor Syndromes	H. Aydın
	12.00-12.50	Insulin and Oral Antidiabetic Drugs I	E. Genç
	13.00-13.50		
	14.00-14.50	Insulin and Oral Antidiabetic Drugs II	E. Genç
	15.00-15.50	Independent study hours	
	16.00-16.50		
	17.00-17.50		
13-Feb-2014	09.00-09.50	Pathophysiology of Reproductive System Diseases	M. Koçak
THURSDAY	10.00-10.50	Pathophysiology of Reproductive System Diseases	M. Koçak
	11.00-11.50	Pathology of Breast I	F. Özkan
	12.00-12.50	Pathology of Breast II	F. Özkan
	13.00-13.50		
	14.00-14.50	Chromosomal Disorders I	A. Ç. Kuşkucu
	15.00-15.50	Chromosomal Disorders II	A.Ç. Kuşkucu
	16.00-16.50	Independent study hours	
	17.00-17.50		
14-Feb-2014			
FRIDAY	09.00-09.50	Pathology of Vulva & Vagina	F. Özkan
	10.00-10.50	Pathology of Cervix Uteri I	F. Özkan
	11.00-11.50	Pathology of Cervix Uteri II	F. Özkan
	12.00-12.50	Independent study hours	
	13.00-13.50		

	14.00-14.50	CSL GROUP IV (Stages of normal labour)	A Somunkıran İş/ O. Api
	15.00-15.50		
	16.00-16.50		
III. WEEK			
DAY	HOURL	SUBJECT	LECTURER
17-Feb-2014	09.00-09.50	Antenatal Care	P. Cenksoy / C. Fıçıcıoğlu
MONDAY	10.00-10.50	Embryology	O. Akçin
	11.00-11.50	Medical History for Breast Diseases in Primary Care BSE & Clinical Breast Examination	A. Akalın
	12.00-12.50	Adrenocortical Hormones and Drugs II	E. Genç
	13.00-13.50		
	14.00-14.50	Sex Chromosomes and their Abnormalities	A.Ç. Kuşkucu
	15.00-15.50	Genetic Disorders of Gonadal Development	A.Ç. Kuşkucu
	16.00-16.50	Microbiology laboratory (Diagnostic tests of urogenital specimens) GROUP I- II	Y.Gurol
	17.00-17.50		
18-Feb-2014	09.00-09.50	The Gynecological History and Examination	A.Somunkıran
TUESDAY	10.00-10.50	Conditions affecting Vulva & Vagina	A.Somunkıran
	11.00-11.50	Delivery of Family Planning Services I	A. Akalın
	12.00-12.50	Delivery of Family Planning Services II	A. Akalın
	13.00-13.50		
	14.00-14.50	General Approach to the Pregnant Woman	Ö. Tanrıöver
	15.00-15.50	Normal Pubertal Development	G.Ç. Erdağ
	16.00-16.50	Pubertal Disorders	G.Ç. Erdağ
	17.00-17.50	Independent study hours	
19-Feb-2014	09.00-09.50	The Menstrual Cycle and Disorders of the Menstrual Cycle	R. Attar
WEDNESDAY	10.00-10.50	Normal and Abnormal Sexual Development & Puberty	R. Attar
	11.00-11.50	Estrogens, Progestins and Inhibitors I	E. Genç
	12.00-12.50	Estrogens, Progestins and Inhibitors II	E. Genç
	13.00-13.50		
	14.00-14.50	Normal and abnormal labor	O. Api
	15.00-15.50	Microbiology laboratory (Diagnostic tests of urogenital specimens) GROUP III-IV	Y.Gurol
	16.00-16.50		
20-Feb-2014	09.00-09.50	Disorders of Early Pregnancy (Miscarriage; Ectopic; GTD)	P. Cenksoy / C. Fıçıcıoğlu
THURSDAY	10.00-10.50	Pathology of Pregnancy & Placenta	F. Özkan
	11.00-11.50	Congenital Infections and Sexually Transmitted Diseases, Genital infections I	G. Çelik
	12.00-12.50	Congenital Infections and Sexually Transmitted Diseases, Genital Infections I	G. Çelik
	13.00-13.50		
	14.00-14.50	Congenital Infections and Sexually Transmitted Diseases, Genital Infections I	M. Sönmezoğlu
	15.00-15.50	CSL GROUP III (Stages of normal labour)	A.Somunkıran/ O. Api
	16.00-16.50		
	17.00-17.50		
21-Feb-2014	09.00-09.50	Endometriosis & Adenomyosis	G.Yıldırım

FRIDAY	10.00-10.50	Puerperal Infections	O. Api
	11.00-11.50	Pathology of Treponemal Infections	F. Özkan
	12.00-12.50	Pathology of Uterus I	F. Özkan
	13.00-13.50		
	14.00-14.50	Pathology of Uterus II	F. Özkan
	15.00-17.50	CSL GROUP II (Stages of normal labour)	A.Somunkıran/ O. Api
	16.00-16.50		
	17.00-17.50		
IV. WEEK			
DAY	HOOR	SUBJECT	LECTURER
24-Feb-2014	09.00-09.50	Benign Diseases of the Uterus and the Cervix	R. Attar
MONDAY	10.00-10.50	Benign Diseases of the Ovary	R. Attar
	11.00-11.50	Malign Diseases of the Ovary	G.Yıldırım
	12.00-12.50	Malign Diseases of the Uterus & Cervix	G.Yıldırım
	13.00-13.50		
	14.00-14.50	Pathology of Ovary I	F. Özkan
	15.00-15.50	Pathology of Ovary I	F. Özkan
25-Feb-2014	09.00-09.50	Menopause	C. Fiçicioğlu
TUESDAY	10.00-10.50	Fertility Control	C. Fiçicioğlu
	11.00-11.50	Infertility	C. Fiçicioğlu
	12.00-12.50		
	13.00-13.50		
	14.00-14.50	CSL GROUP I (Stages of normal labour)	A. Somunkıran/ O. Api
	15.00-15.50		
	16.00-16.50		
28-Feb-2013			
FRIDAY	10.00-13.00	COMMITTEE EXAM	

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**URINARY SYSTEM
COMMITTEE VI
DISTRIBUTION of LECTURE HOURS
March 03, 2013 – March 20 , 2013
COMMITTEE DURATION: 4 WEEKS**

• DISCIPLINE	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
• UROLOGY	URO	7				7
• NEPHROLOGY	NE	13				13
• PATHOLOGY	PT	12		1x2=2 (2 Groups)		14
• PATHOPHYSIOLOGY	PP	2				2
• PHARMACOLOGY	PC	3				3
• PEDIATRICS	PED	1				1
• PUBLIC HEALTH		2				2
• CSL	CSL			1x2=2 (4 Groups) 1x3=3 (4 Groups)		5
• RADIOLOGY	RAD	1				1
• MEDICAL GENETICS	MG	1				1
• INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	2		1x2=2 (2 Groups)		4
• PEDIATRIC SURGERY	PED-S	1				1
• GENERAL SURGERY	GS	1				1
• BIostatISTICS	BS	2			1x2=2	4
• FAMILY MEDICINE	FM	1				1
TOTAL		49		9	2	60

Coordination Committee

HEAD	Gülçin Kantarcı, MD Prof.
SECRETARY	Hakan Koyuncu, MD Assist. Prof.
MEMBER	Faruk Yencilek, MD Assoc. Prof.
MEMBER	Zehra Eren, MD Assist. Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**URINARY SYSTEM
COMMITTEE VI
LECTURERS**

DISCIPLINE	LECTURERS
UROLOGY	Faruk Yencilek, MD Assoc. Prof. Hasbey Hakan Koyuncu, MD Assist. Prof.
NEPHROLOGY	Gülçin Kantarcı, MD Prof. Zehra Eren, MD Assist. Prof.
PATHOLOGY	Ferda Özkan, MD Prof Işın Doğan Ekici MD, Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Koçak, MD PhD
PHARMACOLOGY	Ece Genç, PhD Prof.
PEDIATRICS	Ayça Vitrinel, MD Prof. Filiz Bakar , MD Prof.
PUBLIC HEALTH	Yeşim Yasin
CSL	Filiz Bakar, MD Prof. Oluş Api, MD Assoc. Prof Gazi Yıldırım, MD Assoc. Prof Güldal İzbrak, MD Assist. Prof. Arzu Akalın, MD Assist. Prof. Suat Biçer, MD Assist. Prof.
RADIOLOGY	Ayşegül Sarsılmaz, MD Assist Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Meral Sömnezoğlu, MD Assoc. Prof. İbrahim Çağatay Acuner, MD Assist. Prof.
PEDIATRIC SURGERY	Selami Sözübir, MD Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD PhD Assist Prof.
GENERAL SURGERY	Özcan Gökçe, MD Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD Assist. Prof.
FAMILY MEDICINE	Hülya Akan, MD Assoc. Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**URINARY SYSTEM
COMMITTEE VI**

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. **to remind** knowledge on anatomy, histology and physiology of urinary system,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to urinary system,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to urinary system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, **at the** level of primary health care service,
7. **to convey** knowledge on pharmacology of drugs that are effective on urinary system or on clinical conditions involving urinary system,
8. **to convey** knowledge on genetics of urinary system,
9. **to convey** knowledge on phytotherapeutic agents that are effective on urinary system or on clinical conditions involving urinary system,
10. **to convey** knowledge on use of biostatistical software and presentation of results,
11. **to convey** knowledge on legal regulations and ethical principles related to reproductive care,
12. **to equip with** basic and advanced clinical skills (*gynecological examination-C6, "Pap-smear" collection-C6, intrauterine device placement-C6, breast examination-C6, physical examination in neonate, infant and prepubertal/pubertal child-C6*) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1. **recall** anatomy, histology and physiology of urinary system,
2. **explain** etiopathogenesis of clinical conditions (renal hemodynamics, acid-base equilibrium, renal clinical conditions, urinary system stones, urinary system infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
3. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
4. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to urinary system,
5. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
6. at multi-system level and/or related to urinary system,
 - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
 - health care processes, clinical decision making process, clinical decisions and clinical practiceswhich are required for management at primary health care service level:
- 6.1. practice of history taking and physical examination (neonatal, prepubertal/pubertal-C6)
- 6.2. evaluation of emergency case (urological emergencies-C6)
- 6.3. approach to healthy individual or patient (urethral-vaginal-cervical discharge/swab specimen-C6, fecal specimen collection-C6)
- 6.4. laboratory tests/examinations (urethral-vaginal-cervical discharge culture-C6, fecal culture-C6)
- 6.5. imaging tests/examinations (uroradiology-C6, renal scintigraphy (GFR, ERPF, Renogram)-C6)
- 6.6. point of care testing
- 6.7. making preliminary diagnosis or definitive diagnosis decision
- 6.8. making non-intervention or intervention decision
- 6.9. practicing non-intervention or intervention
- 6.10. referral/transport of healthy individual or patient
7. **explain** pharmacology of drugs that are effective on urinary system or on clinical conditions involving urinary system,
8. **explain** pharmacology of androgens and anabolic steroids, and drugs that affect bone mineral homeostasis,
9. **explain** genetics of urinary system,
10. **explain** mechanisms of action for phytotherapeutic agents that are effective on urinary system or in clinical conditions related to urinary system,
11. **define** use of biostatistical software and presentation of results,
12. **perform** basic clinical skills, practiced on phantom models, and advanced clinical skills, practiced on simulated/standardized patients (gynecological examination-C6, "Pap-smear" collection-C6, intrauterine device placement-C6, breast examination-C6, physical examination in neonate, infant and prepubertal/pubertal child-C6), required at primary health care service.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

PHASE III COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES COURSE COMPONENT: COMMITTEE VI URINARY SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0.-6.0.	GS	Ö. Gökçe	2	0	0	2
1.0.-6.0.	NE	G. Kantarcı	14	4	2	20
1.0.-6.0.	NE	Z. Eren	7	3	1	11
1.0.-6.0.	PED	A. Vitrinel	2	1	0	3
1.0.-6.0.	PED-S	S. Sözübir	2	1	0	3
1.0.-6.0.	URO	F. Yencilek	7	2	2	11
1.0.-6.0.	URO	H. Koyuncu	5	1	1	7
1.0., 2.0., 5.0., 6.4.	PT	I.D. Ekici	21	6	3	30
2.0., 5.0.	PP	M. Koçak	2	1	0	3
2.0.-6.0.	IDCM	M. Sönmezoglu	3	1	0	3
2.0.-5.0., 6.4.	IDCM	G. Çelik	3	0	0	3
3.0., 4.0.	PH	Y.Yasin	3	1	1	5
6.3.	FM	H. Akan	2	1	0	3
6.5.	RAD	A. Sarsılmaz	2	0	0	2
7.0., 8.0.	PC	E. Genç	5	1	1	7
9.0.	MG	A.Ç. Kuskucu	3	0	0	3
11.0.	BS	Ç. Kaspar	7	2	1	10
TOTAL			90	25/200	12/100	127
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.-6.0.	URO	F. Yencilek	2	-	-	2
1.0.-6.0.	NE	G. Kantarcı	2	-	-	2
1.0., 2.0., 5.0., 6.4.	PT	I.D. Ekici	1	-	-	1
TOTAL			5	-	-	5

PHASE III		COMMITTEE VI	URINARY SYSTEM
I. WEEK			
DAY	HOUR	SUBJECT	LECTURER
03-Mar-2014	09.00-09.50	<i>Independent study hours</i>	
MONDAY	10.00-10.50		
	11.00-11.50	Pathophysiology of Urinary System Diseases I	M. Koçak
	12.00-12.50	Pathophysiology of Urinary System Diseases II	M. Koçak
	13.00-13.50		
	14.00-14.50	Renovascular Pathology	I D. Ekici
	15.00-15.50	Renal Cystic Disease	I D. Ekici
	16.00-16.50	<i>Independent study hours</i>	
	17.00-17.50		
04-Mar-2014	09.00-09.50	Obstructive Uropathy, Urolithiasis	F. Yencilek
TUESDAY	10.00-10.50	Urologic Emergencies	F. Yencilek
	11.00-11.50	Pathology of Male Genital System I	I. D. Ekici
	12.00-12.50	Pathology of Male Genital System II	I. D. Ekici
	13.00-13.50		
	14.00-14.50	Urinary Findings	G. Kantarcı
	15.00-15.50	Nephritic Syndrome	G. Kantarcı
	16.00-16.50	Nephrotic Syndrome	G. Kantarcı
	17.00-17.50	<i>Independent study hours</i>	
05-Mar-2014	09.00-09.50	Pathology of Tubulointerstitial Disease I	I. D. Ekici
WEDNESDAY	10.00-10.50	Pathology of Tubulointerstitial Disease II	I. D. Ekici
	11.00-11.50	Tubulointerstitial Diseases I	G. Kantarcı
	12.00-12.50	Tubulointerstitial Diseases I	G. Kantarcı
	13.00-13.50		
	14.00-14.50	Using Statistical Programs	Ç. Kaspar
	15.00-15.50	Using Statistical Programs	Ç. Kaspar
	16.00-16.50	<i>Independent study hours</i>	
	17.00-17.50		
06-Mar-2014	09.00-09.50	Acute Kidney Injury I	G. Kantarcı
THURSDAY	10.00-10.50	Acute Kidney Injury II	G. Kantarcı
	11.00-11.50	Pathology of Glomerular Diseases I	I D. Ekici
	12.00-12.50	Pathology of Glomerular Diseases II	I D. Ekici
	13.00-13.50		
	14.00-14.50	CSL Group I (<i>Gynecological examination, PAP smear obtaining and insertion of IUD / Physical examination of breast and breast self exam</i>)	G. Yıldırım /
	15.00-15.50		O. Apı /
	16.00-16.50		A. Akalın/ G. İzbrak
07-Mar-2014	09.00-09.50	Upper and Lower Urinary Tract Infections I	G. Çelik
FRIDAY	10.00-10.50	Upper and Lower Urinary Tract Infections I	M. Sönmezoğlu
	11.00-11.50	Nephritic and Nephrotic Syndrome	A. Vitrinel
	12.00-12.50	Approach to the Urinary Tract Infections	H. Akan
	13.00-13.50		
	14.00-14.50	<i>Independent study hours</i>	
	15.00-15.50		
	16.00-16.50		
	17.00-17.50		

III. WEEK			
DAY	HOOR	SUBJECT	LECTURER
17-Mar-2014	09.00-09.50	Agents Effecting Bone Mineral Homeostasis I	E. Genç
MONDAY	10.00-10.50	Agents Effecting Bone Mineral Homeostasis II	E. Genç
	11.00-11.50	Androgens & Anabolic Steroids	E. Genç
	12.00-12.50	Inherited Renal Disorders	A.Ç. Kuşkucu
	13.00-13.50		
	14.00-14.50	CSL Group II (<i>Gynecological examination, PAP smear obtaining and insertion of IUD / Physical examination of breast and breast self exam</i>)	G. Yıldırım /
	15.00-15.50		O. Açı /
	16.00-16.50		A. Akalın/ G. İzbirak
	17.00-17.50		
18-Mar-2014	09.00-09.50	Independent study hours	
TUESDAY	10.00-10.50		
	11.00-11.50	Pathology Group I	F. Özkan/I.D.
	12.00-12.50		Ekici
	13.00-13.50		
	14.00-14.50	Pathology Group II	F. Özkan/I.D.
	14.00-14.50		Ekici
19-Mar-2014	09.00-09.50	Congenital Anomalies of The Urinary System	S. Sözübir
WEDNESDAY	10.00-10.50		
	11.00-11.50	The Kidney Systemic Disease and Inherited Disorders I	Z. Eren
	12.00-12.50	The Kidney Systemic Disease and Inherited Disorders II	Z. Eren
	13.00-13.50		
	14.00-14.50	CSL Group IV (Physical examination of the newborn and child patient)	F. Bakar/ S. Biçer
	15.00-15.50		
	16.00-16.50	CSL Group III (Physical examination of the newborn and child patient)	F. Bakar/ S. Biçer
	17.00-17.50		
20-Mar-2014	09.00-09.50	The presentation of the results	Ç. Kaspar
THURSDAY	10.00-10.50	The presentation of the results	Ç. Kaspar
	11.00-11.50	Chronic Kidney Disease I	G. Kantarcı
	12.00-12.50	Chronic Kidney Disease II	G. Kantarcı
	13.00-13.50		
	14.00-14.50	CSL Group II (Physical examination of the newborn and child patient)	F. Bakar/ S. Biçer
	15.00-15.50		
	16.00-16.50	CSL Group I (Physical examination of the newborn and child patient)	F. Bakar/ S. Biçer
	17.00-17.50		
21-Mar-2013	09.00-09.50	Male Infertility	H. Koyuncu
FRIDAY	10.00-10.50	Transplantation of Kidney	Ö. Gökçe
	11.00-11.50	Imaging of Urinary System	A. Sarsılmaz
	12.00-12.50		
	13.00-13.50		
	14.00-14.50	Independent study hours	
	15.00-15.50		
	16.00-16.50		

IV. WEEK			
DAY	HOUR	SUBJECT	LECTURER
24-27-Mar-2014	09.00-09.50	<i>Independent study hours</i>	
MONDAY	10.00-10.50		
	11.00-11.50		
	12.00-12.50		
	13.00-13.50		
	14.00-14.50		
	15.00-15.50		
	16.00-16.50		
	17.00-17.50		
28-Mar-2014	10:00-13:00	COMMITTEE EXAM	
FRIDAY			

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**NERVOUS SYSTEM and PSYCHIATRY
COMMITTEE VII
DISTRIBUTION of LECTURE HOURS
MARCH 31, 2014 – May 06 , 2014
COMMITTEE DURATION: 6 WEEKS**

• DISCIPLINE	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
• NEUROLOGY	NR	13	1x4=4 (2 Groups)			17
• PSYCHIATRY	PCH	10				10
• CHILD PSYCHIATRY	C-PCH	6				6
• NEUROSURGERY	NRS	16	1x2=2 (2 Groups)			18
• PATHOLOGY	PT	12		1x2=2 (2 Groups)		14
• PATHOPHYSIOLOGY	PP	2				2
• PHARMACOLOGY	PC	14				14
• PEDIATRICS	PED	4				4
• PUBLIC HEALTH	PH	2				2
• FAMILY MEDICINE	FM	5				5
• CSL	CSL			2x3=6 (4 Groups)		6
• RADIOLOGY	RAD	1				1
• MEDICAL GENETICS	MG	2				2
• INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	2				2
• OPHTHALMOLOGY	OPT	3				3
• ANESTHESIOLOGY & REANIMATION	ANS	2				2
• BIOSTATISTICS	BS	2			1x2=2	4
• SCIENTIFIC PROJECT-S III	SPW	1				1
TOTAL		97	6	8	2	113

Coordination Committee

HEAD	Berrin Aktekin, MD Prof.
SECRETARY	Oğuzhan Zahmacıoğlu, MD Assist. Prof.
MEMBER	Burcu Örmeci, MD Assist. Prof.
MEMBER	Berfu Akbaş, MD Assist. Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**NERVOUS SYSTEM and PSYCHIATRY
COMMITTEE VII
LECTURERS**

DISCIPLINE	LECTURERS
NEUROLOGY	Berrin Aktekin, MD Prof. Burcu Örmeci, MD Assist. Prof.
PSYCHIATRY	N. Berfu Akbaş, MD Assist. Prof. Hakan Atalay, MD Assist. Prof.
CHILD PSYCHIATRY	Oğuzhan Zahmacıoğlu, MD Assist. Prof.
NEUROSURGERY	Uğur Türe, MD Prof. Başar Atalay, MD Prof.
PATHOLOGY	Ferda Özkan, MD Prof. Işın Doğan Ekici, MD Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Koçak, MD PhD
PHARMACOLOGY	Ece Genç, PhD Prof.
PEDIATRICS	Ayça Vitrinel, MD Prof. Reha Cengizlier, MD Prof.
PUBLIC HEALTH	Selma Karabey, MD, Prof.
CSL	Burcu Uğurel, MD Assist Prof. Berfu Akbaş, MD Assist. Prof. Uğur Anıl Bingöl, MD Assist. Prof. Pınar Samut, MD Assist. Prof.
FAMILY MEDICINE	Güldal İzbirak, MD Assist. Prof. Özlem Tanrıöver, MD Assist. Prof. Hülya Akan, MD Assoc. Prof. Ayşe Arzu Akalın, MD Assist. Prof.
RADIOLOGY	Basar Sarıkaya, MD Assoc. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Gülden Çelik, MD Prof. Meral Sömnecoğlu, MD Assoc. Prof.
OPHTHALMOLOGY	Canan Aslı Yıldırım, MD Assoc. Prof. Vildan Öztürk, MD Assist. Prof.
ANESTHESIOLOGY & REANIMATION	Özge Köner, MD Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD PhD. Assist Prof
BIOSTATISTICS	Çiğdem Kaspar, PhD Assist. Prof.
SCIENTIFIC PROJECTS- III	Gülderen Yanıkkaya Demirel, MD Assoc. Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**NERVOUS SYSTEM and PSYCHIATRY
COMMITTEE VII**

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. **to remind** knowledge on anatomy, histology and physiology of nervous system,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to nervous system and psychiatry, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. **to convey** necessary knowledge on drugs that are effective on nervous system or on clinical conditions related to nervous system and psychiatry ,
8. **to convey** necessary knowledge on professional standards, organizational ethics, and ethics of psychiatry,
9. **to convey** necessary knowledge on common problems in medical research,
10. **to convey** knowledge on phytotherapeutic agents,
11. **to equip with** basic and advanced clinical skills (*suturing and tying-C7, neuropsychiatric evaluation-C7*) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

- 1.0. **recall** anatomy, histology and physiology of nervous system,
- 2.0. **define** biochemical and psychodynamical basis of behavior,
- 3.0. **grade** physical, psychosocial and cognitive development of child,
- 4.0. **explain** etiopathogenesis of clinical conditions (central and peripheral nervous system disorders, epilepsy, organic brain syndromes, CNS tumors, psychiatric disorders/diseases) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
- 5.0. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
- 6.0. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,
- 7.0. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
- 8.0. at multi-system level and/or related to cardiovascular and respiratory systems system,
 - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
 - health care processes, clinical decision making process, clinical decisions and clinical practiceswhich are required for management at primary health care service level:
- 8.1. practice of history taking and physical examination (neurological/neuropsychiatric-C7)
- 8.2. evaluation of emergency case (neurological emergencies-C7)
- 8.3. approach to healthy individual or patient (neurological symptoms-C7, headache-C7, depression-C7, dementia-C7)
- 8.4. laboratory tests/examinations
- 8.5. imaging tests/examinations (conventional neuroradiological examinations-C7, spinal neuroradiology-C7, cranial CT-C7, cranial MRI-C7, brain perfusion scintigraphy-C7, brain PET-C7)
- 8.6. point of care testing
- 8.7. making preliminary diagnosis or definitive diagnosis decision
- 8.8. making non-intervention or intervention decision
- 8.9. practicing non-intervention or intervention
- 8.10. referral/transport of healthy individual or patient
- 9.0. **explain** pharmacology of drugs (parkinsonism and other movement disorders, antiepileptics, CNS stimulants and hallucinogenic drugs, sedative/hypnotic drugs, opioid analgesics and antagonists, general/local anesthetics, antipsychotic drugs, bipolar disease and lithium, antidepressant drugs, alcohols, drug dependence and abuse) that are effective on nervous system or on clinical conditions related to nervous system and psychiatry,
- 10.0. **describe** professional standards, organizational ethics, and ethics in psychiatry,
- 11.0. **describe** phytotherapeutic agents ("HMPs, Nutraceuticals"),
- 12.0. **list** common problems in medical research,
- 13.0. **perform** basic clinical skills, practiced on phantom models (suturing and tying-C7), and advanced clinical skills, practiced on simulated/standardized patients (neuropsychiatric evaluation-C7), required at primary health care service.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

PHASE III COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES COURSE COMPONENT: COMMITTEE VII NERVOUS SYSTEM and PSYCHIATRY						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0., 2.0., 4.0.-8.0., 10.0.	PCH	H. Atalay	3	1	0	4
1.0., 2.0., 4.0.-8.0., 10.0.	PCH	B.Akbas	5	1	1	7
1.0., 3.0.-8.0.	PED	R. Cengizlier	1	2	0	3
1.0., 3.0.-8.0.	PED	A.Vitrinel	3	1	0	4
1.0., 4.0., 7.0.	PT	F. Özkan	5	1	1	7
1.0., 4.0., 7.0.	PT	I.D. Ekici	5	1	1	7
1.0., 4.0.-8.0.	ANS	Ö. Köner	2	0	0	2
1.0., 4.0.-8.0.	NR	B. Aktekin	6	1	0	7
1.0., 4.0.-8.0.	NR	B. Örmeci	7	2	2	11
1.0., 4.0.-8.0.	NRS	B. Atalay	11	3	2	16
1.0., 4.0.-8.0.	NRS	U. Türe	4	1	1	6
1.0., 4.0.-8.0.	OPT	C.A.Yıldırım	2	0	0	2
1.0., 4.0.-8.0.	OPT	V. Öztürk	1	1	0	2
2.0.	MG	A.Ç. Kuskucu	3	0	0	3
2.0.-8.0., 10.0.	C-PCH	O. Zahmacıoglu	5	1	1	7
4.0., 7.0.	PP	M. Koçak	2	0	0	2
4.0.-7.0, 8.4.	IDCM	G. Çelik	1	1	0	2
4.0.-8.0.	IDCM	M. Sönmezoglu	1	1	0	2
5.0., 6.0.	PH	S.Karabey	2	0	0	2
8.3.	FM	H. Akan	2	1	0	3
8.3.	FM	G. Izbirak	1	1	0	2
8.3.	FM	A.Akalın	1	0	0	1
8.5.	RAD	B. Sarıkaya	1	1	0	2
9.0.	PC	E. Genç	13	3	3	19
12.0.	BS	Ç. Kaspar	3	1	0	4
TOTAL			90	25/200	12/100	127
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0., 4.0.-8.0.	NR	B. Örmeci	2	-	-	2
1.0., 2.0., 4.0.-8.0., 10.0.	PCH	H. Atalay	2	-	-	2
1.0., 4.0.-8.0.	NRS	B. Atalay	1	-	-	1
TOTAL			5	-	-	5

PHASE III	COMMITTEE VII NERVOUS SYSTEM and PSYCHIATRY		
I. WEEK			
DAY	HOUR	SUBJECT	LECTURER
31-Mar-2014	09.00-09.50	<i>Independent study hours</i>	
MONDAY	10.00-10.50	Signs and Symptoms in Neurology	B. Aktekin
	11.00-11.50	Pathophysiology of Nervous System Diseases I	M. Koçak
	12.00-12.50	Pathophysiology of Nervous System Diseases II	M. Koçak
	13.00-13.50		
	14.00-14.50	Social Determinants of Health and Disease	S.Karabey
	15.00-15.50	Epidemiology of Neurologic Disorders	S.Karabey
	16.00-16.50		
	17.00-17.50	<i>Independent study hours</i>	
01-Apr-2014	09.00-09.50	Infectious Diseases of CNS I	F. Özkan
TUESDAY	10.00-10.50	Infectious Diseases of CNS II	F. Özkan
	11.00-11.50	Cerebral Lobes and their Disorders	B. Örmeci
	12.00-12.50	Infectious Disease of the Nervous System	R. Cengizlier
	13.00-13.50		
	14.00-14.50	Cranial Nerves I	B. Aktekin
	15.00-15.50	Cranial Nerves II	B. Aktekin
	16.00-16.50		
	17.00-17.50	<i>Independent study hours</i>	
02-Apr-2014	09.00-09.50	Demyelinating Disorders	B. Örmeci
WEDNESDAY	10.00-10.50	Demyelinating Disorders	B. Örmeci
	11.00-11.50	Clinical Presentation, Anatomic Concepts and Diagnosis in a Neurosurgical Patient	B. Atalay
	12.00-12.50	Pediatric Neurosurgery	B. Atalay
	13.00-13.50		
	14.00-14.50	Hydrocephalus	B. Atalay
	15.00-15.50	Reading Medical Articles	Ç. Kaspar
	16.00-16.50	Reading Medical Articles	Ç. Kaspar
03-Apr-2014	09.00-09.50	Cerebrovascular Disease	B. Örmeci
THURSDAY	10.00-10.50	Extrapyramidal System Disorders	B. Örmeci
	11.00-11.50	Dementia	B. Örmeci
	12.00-12.50	Pathology of Myelin & Neuronal Storage Diseases I	I.D. Ekici
	13.00-13.50		
	14.00-14.50	Pathology of Myelin & Neuronal Storage Diseases I	I.D. Ekici
	15.00-15.50	Some Common Problems in Medical Research	Ç. Kaspar
	16.00-16.50	Some Common Problems in Medical Research	Ç. Kaspar
	17.00-17.50	<i>Independent study hours</i>	
04-Apr-2014	09.00-09.50	Peripheral Nerve Disorders	B. Aktekin
FRIDAY	10.00-10.50	Introduction to Central Nervous System Pharmacology	E. Genç
	11.00-11.50	Pharmacological Approach to Parkinsonism & Other Movement Disorders	E. Genç
	12.00-12.50	Acute and Chronic Meningitis, Encephalitis I	G. Çelik
	13.00-13.50		
	14.00-14.50	Acute and Chronic Meningitis, Encephalitis II	M. Sönmezoğlu
	15.00-15.50	Scientific Projects- III: Writing Project	G. Yanıkkaya Demirel

II. WEEK			
DAY	HOUR	SUBJECT	LECTURER
07-Apr-2014	09.00-09.50	Neurodegenerative Disorders	A.Vitrinel
MONDAY	10.00-10.50	Neurodegenerative Disorders I	F. Özkan
	11.00-11.50	Neurodegenerative Disorders II	F. Özkan
	12.00-12.50	Antiepileptics	E. Genç
	13.00-13.50		
	14.00-14.50	Neurosurgical Infections	B. Atalay
	15.00-15.50	Spinal Cord Compression and Spinal Tumors	B. Atalay
	16.00-16.50	Peripheral Nerve Compression Syndromes	B. Atalay
	17.00-17.50	Independent study hours	
08-Apr-2014	09.00-09.50	Epilepsy	B. Aktekin
TUESDAY	10.00-10.50	Headache in Primary Care	A. Akalın
	11.00-11.50	Headache in Neurologic Patient	B. Örmeci
	12.00-12.50	Cranial Trauma & Intracranial Hemorrhage I	F. Özkan
	13.00-13.50		
	14.00-14.50	Cranial Trauma & Intracranial Hemorrhage II	F. Özkan
	15.00-15.50		
	16.00-16.50	Independent study hours	
	17.00-17.50		
09-Apr-2014	09.00-09.50		
WEDNESDAY	10.00-10.50	Neurology Clinical Study & Practice Group I	B. Örmeci
	11.00-11.50		
	12.00-12.50		
	13.00-13.50		
	14.00-14.50	Independent study hours	
	15.00-15.50	CNS Stimulants & Hallusinogenic Drugs	E. Genç
	16.00-16.50	Sedative/Hypnotic Drugs I	E. Genç
	17.00-17.50	Independent study hours	
10-Apr-2014	09.00-09.50	Surgical Neuroanatomy	U. Türe
THURSDAY	10.00-10.50	Cerebrovascular Diseases in Neurosurgery I	U. Türe
	11.00-11.50	Cerebrovascular Diseases in Neurosurgery II	U. Türe
	12.00-12.50	Cranial Trauma in Neurosurgery	B. Atalay
	13.00-13.50		
	14.00-14.50	Spinal Trauma in Neurosurgery	B. Atalay
	15.00-15.50		
	16.00-16.50	Independent study hours	
	17.00-17.50		
11-Apr-2014	09.00-09.50		
FRIDAY	10.00-10.50	Neurology Clinical Study & Practice Group II	B. Örmeci
	11.00-11.50		
	12.00-12.50		
	13.00-13.50		
	14.00-14.50	Pathology Lab Group III-IV	F.Özkan/I.D.Ekici
	15.00-15.50		

III. WEEK			
DAY	HOURL	SUBJECT	LECTURER
14-Apr-2014	09.00-09.50	Intracranial tumors I	U. Türe
MONDAY	10.00-10.50	Intracranial tumors II	U. Türe
	11.00-11.50	Degenerative Diseases of the Spine and the Spinal Cord I	B. Atalay
	12.00-12.50	Degenerative Diseases of the Spine and the Spinal Cord II	B. Atalay
	13.00-13.50		
	14.00-14.50	Tumors of CNS I	I.D. Ekici
	15.00-15.50	Tumors of CNS II	I.D. Ekici
	16.00-16.50	Independent study hours	
	17.00-17.50		
15-Apr-2014	09.00-09.50	Functional Neurosurgery	B. Atalay
TUESDAY	10.00-10.50	Neurosurgery: Clinical Practice –I	B. Atalay
	11.00-11.50		
	12.00-12.50	Cerebral Malformations	A. Vitrinel
	13.00-13.50		
	14.00-14.50	Sedative / Hypnotic Drugs II	E. Genç
	15.00-15.50	Independent study hours	
	16.00-16.50		
	17.00-17.50		
16-Apr-2014	09.00-09.50	Mental and Motor Development	A. Vitrinel
WEDNESDAY	10.00-10.50	Conventional Neuroradiological Examinations	B.Sarıkaya
	11.00-11.50	Genetic Etiology of Mental Retardation I	A.Ç. Kuşkucu
	12.00-12.50	Genetic Etiology of Mental Retardation II	A.Ç. Kuşkucu
	13.00-13.50		
	14.00-14.50	Independent study hours	
	15.00-15.50		
	16.00-16.50		
	17.00-17.50		
17-Apr-2014	09.00-09.50	Neurosurgery: Clinical Practice –II	B. Atalay
THURSDAY	10.00-10.50		
	11.00-11.50	Opioid Analgesics & Antagonists I	E. Genç
	12.00-12.50	Opioid Analgesics & Antagonists II	E. Genç
	13.00-13.50		
	14.00-14.50	Neurological emergencies	B. Örmeci
	15.00-15.50	Independent study hours	
	16.00-16.50		
	17.00-17.50		
18-Apr-2014	09.00-09.50	Diseases of Optic Nerves and Visual Fields	C.A.Yıldırım
FRIDAY	10.00-10.50	Pupilla	C.A.Yıldırım
	11.00-11.50	Introduction to General Anesthesia	Ö. Köner
	12.00-12.50	Anesthetic agents	Ö. Köner
	13.00-13.50		
	14.00-14.50	Independent study hours	
	15.00-15.50	Approach to Smoking Patient in Primary Care	H. Akan
	16.00-16.50	Depression in Primary Care	G. İzbirak
	17.00-17.50	Independent study hours	

IV. WEEK			
DAY	HOURL	SUBJECT	LECTURER
21-Apr-2014	09.00-09.50	Introduction to Psychiatry	H. Atalay
MONDAY	10.00-10.50	Signs and Symptoms in Psychiatry	H. Atalay
	11.00-11.50	Developmental Psychopathology: Risk and Protective Factors in Mental Development	H. Atalay
	12.00-12.50	General Anesthetics	E. Genç
	13.00-13.50		
	14.00-14.50	Pathology lab I-II	F.Özkan/I.D. Ekici
	15.00-15.50		
22-Apr-2014	09.00-09.50	Schizophrenia and Psychosis I	H. Atalay
TUESDAY	10.00-10.50	Schizophrenia and Psychosis II	H. Atalay
	11.00-11.50	Local Anesthetics	E. Genç
	12.00-12.50	Genetic Aspects of Psychiatric Disorders	A.Ç. Kuşku
	13.00-13.50		
	14.00-14.50	Culture, Health and Illness	S.Karabey
	14.00-14.50	Epidemiology of Mental Disorders	S.Karabey
	14.00-14.50	Behavioral Determinants of Health and Disease	S.Karabey
	15.00-15.50	Independent study hours	
	16.00-16.50		
	17.00-17.50		
23-Apr-2014		National Hoilday	
WEDNESDAY			
24-Apr-2014	09.00-09.50	Common Childhood Psychiatric Problems	O. Zahmacioğlu
THURSDAY	10.00-10.50	Attention Deficit Disorders, Pervasive Developmental Disorders	O. Zahmacioğlu
	11.00-11.50	Childrens' Rights, Issues about Child Abuse and Neglect	O. Zahmacioğlu
	12.00-12.50	Developmental Disorders of CNS	I.D. Ekici
	13.00-13.50		
	14.00-14.50	Approach to the Patient with Dementia in Primary Care	H. Akan
	15.00-15.50	Independent study hours	
	16.00-16.50		
	17.00-17.50		
25-Apr-2014	09.00-09.50	Drug Addiction & Alcoholism	B.Akbaş
FRIDAY	10.00-10.50	Organic Brain Syndromes	B.Akbaş
	11.00-11.50	Mood Disorders	B.Akbaş
	12.00-12.50	Paralytic Strabismus and Nistagmus	V. Öztürk
	13.00-13.50		
	14.00-14.50	Independent study hours	
	15.00-15.50		
	16.00-16.50		
	17.00-17.50		

VI. WEEK			
DAY	HOURL	SUBJECT	LECTURER
05-May-2014	09.00-09.50	CSL group IV	Uğur Anıl Bingöl/
MONDAY	10.00-10.50	<i>(Suturing materials and suturing technique)</i>	Pınar Samut
	11.00-11.50		
	12.00-12.50		
	13.00-13.50	CSL Group II	B. Örmeci/B.Akbaş
	14.00-14.50	<i>(Neuropsychiatric assessment)</i>	
	15.00-15.50		
06-May-2014	09.00-09.50	CSL Group IV	B. Örmeci/B.Akbaş
TUESDAY	10.00-10.50	<i>(Neuropsychiatric assessment)</i>	
	11.00-11.50		
	12.00-12.50		
	13.00-13.50		
	14.00-14.50		
	15.00-15.50		
	16.00-16.50		
	17.00-17.50		
07-08-May-2014	09.00-09.50	Independent study hours	
	10.00-10.50		
	11.00-11.50		
	12.00-12.50		
	13.00-13.50		
	14.00-14.50		
	15.00-15.50		
	16.00-16.50		
	17.00-17.50		
09-May-2014	10.00-13.00	COMMITTEE EXAM	
FRIDAY			

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**MUSCULOSKELETAL SYSTEM
COMMITTEE VIII
DISTRIBUTION of LECTURE HOURS
MAY 12, 2014 – JUNE 02, 2014
COMMITTEE DURATION: 4 WEEKS**

• DISCIPLINE	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
• ORTHOPAEDICS & TRAUMATOLOGY	ORT	24	1x3=3 (4 Groups)			27
• PHYSICAL THERAPY & REHABILITATION	PTR	4				4
• RHEUMATOLOGY	RHE	8				8
• PATHOLOGY	PT	11		1x2=2 (4 Groups)		13
• PATHOPHYSIOLOGY	PP	2				2
• PHARMACOLOGY	PC	7				7
• PUBLIC HEALTH	PH	5				5
• FAMILY MEDICINE	FM	2				2
• CSL	CSL			1x3=3 (4 Groups)		3
• MEDICAL GENETICS	MG	2				2
• RADIOLOGY	RAD	1				1
• BIOMEDICAL ETHICS & DEONTOLOGY	BED	2				2
• EMERGENCY MEDICINE	EM	1				1
• BIOSTATISTICS	BS	2			1x2	4
TOTAL		71	3	5	2	81

Coordination Committee

HEAD	Faik Altıntaş, MD Prof.
SECRETARY	Müge Bıçakçıl, MD Assist. Prof.
MEMBER	Ece Aydoğ, MD Prof.
MEMBER	Turhan Özler, MD Assist. Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**MUSCULOSKELETAL SYSTEM
COMMITTEE VIII
LECTURERS**

DISCIPLINE	FACULTY
ORTHOPAEDICS & TRAUMATOLOGY	Faik Altıntaş, MD Prof. Melih Güven, MD Assoc.Prof. Turhan Özler, MD Assist. Prof. Çağatay Uluçay, MD Assist. Prof.
PHYSICAL THERAPY & REHABILITATION	Ece Aydoğ, MD Prof.
RHEUMATOLOGY	Müge Bıçakçıl, MD Assist. Prof
PATHOLOGY	Ferda Özkan, MD Prof Işın Doğan Ekici, MD Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Koçak, MD PhD
PHARMACOLOGY	Ece Genç, PhD Prof.
PUBLIC HEALTH	Selma Karabey,MD,Prof
FAMILY MEDICINE	Özlem Tanrıöver, MD Assist. Prof Hülya Akan, MD Assoc. Prof.
CSL	Çağatay Uluçay, MD Assist. Prof. Turhan Özler, MD Assist. Prof
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
RADIOLOGY	Ayşegül Sarsılmaz, MD Assist. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD PhD Assist Prof.
EMERGENCY MEDICINE	Can Aktaş, MD Assist. Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD Assist. Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**MUSCULOSKELETAL SYSTEM
COMMITTEE VIII**

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. **to remind** knowledge on anatomy, histology and physiology of musculoskeletal system,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to musculoskeletal system,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to musculoskeletal system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. **to convey** necessary knowledge on pharmacology of drugs that are effective on musculoskeletal system or on clinical conditions related to musculoskeletal system,
8. **to convey** necessary knowledge on ethics in biomedical research,
9. **to convey** necessary knowledge on clinical research methods and searching medical literature,
10. **to convey** necessary knowledge on phytotherapeutic agents,
11. **to equip with** basic and advanced clinical skills (peripheral venous catheter insertion-C8, physical examination of musculoskeletal system-C8) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

- 1.0. **recall** anatomy, histology and physiology of musculoskeletal system,
- 2.0. **explain** etiopathogenesis of clinical conditions (congenital, traumatic, metabolic, degenerative, onocological conditions of bone, rheumatological disorders, diseases/disorders of connective tissue, vascular diseases, pathological posture, pain) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
- 3.0. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
- 4.0. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to musculoskeletal system,
- 5.0. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
- 6.0. at multi-system level and/or related to cardiovascular and respiratory systems system,
 - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
 - health care processes, clinical decision making process, clinical decisions and clinical practiceswhich are required for management at primary health care service level:
- 6.1. practice of history taking and physical examination (musculoskeletal-C8)
- 6.2. evaluation of emergency case (trauma-C8)
- 6.3. approach to healthy individual or patient (musculoskeletal dysfunction-C8)
- 6.4. laboratory tests/examinations (monitorization of drug therapy-C8)
- 6.5. imaging tests/examinations (radiological imaging of musculoskeletal system-C8, radiological examinations in benign ve malign tumors of bones-C8, bone scintigraphy-C8)
- 6.6. point of care testing
- 6.7. making preliminary diagnosis or definitive diagnosis decision
- 6.8. making non-intervention or intervention decision
- 6.9. practicing non-intervention or intervention
- 6.10. referral/transport of healthy individual or patient
- 7.0. **explain** pharmacology of drugs (non-opioid analgesics, skeletal muscle relaxants) that are effective on musculoskeletal system or on clinical conditions related to musculoskeletal system,
- 8.0. **explain** effects of phytotherapeutic agents on musculoskeletal system or on clinical conditions related to musculoskeletal system,
- 9.0. **list** ethical principles in biomedical research,
- 10.0. **explain** use of biostatistics in clinical research and for evidence search in medical literature,
- 11.0. **perform** basic clinical skills, practiced on phantom models (peripheral venous catheter insertion-C8), and advanced clinical skills, practiced on simulated/standardized patients (physical examination of musculoskeletal system-C8), required at primary health care service.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

PHASE III COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES COURSE COMPONENT: COMMITTEE VIII MUSCULOSKELETAL SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0.-6.0.	ORT	F. Altıntas	6	2	1	9
1.0.-6.0.	ORT	T. Özler	4	1	1	6
1.0.-6.0.	ORT	Ç. Uluçay	11	3	2	16
1.0.-6.0.	ORT	M. Güven	8	2	1	11
1.0.-6.0.	PTR	E. Aydog	4	1	1	6
1.0.-6.0.	RHE	M. Bıçakçıl	8	2	1	11
1.0., 2.0., 5.0.	PP	M. Koçak	2	1	0	3
1.0., 2.0., 5.0.	PT	F. Özkan	10	2	1	13
1.0., 2.0., 5.0.	PT	I.D.Ekici	6	1	1	8
2.0.	MG	A.Ç.Kuskucu	2	1	0	3
3.0., 4.0.	PH	S.Karabey	7	2	1	10
6.2.	EM	C. Aktas	1	0	0	1
6.3.	FM	H. Akan	1	1	0	2
6.3.	FM	Ö. Tanrıöver	1	1	0	2
6.5.	RAD	A.Sarsılmaz	1	1	0	2
7.0.	PC	S. Alpan	6	1	1	8
7.0.	PC	E. Genç	3	1	0	4
9.0.	BED	E. Vatanoglu	3	1	0	4
10.0.	BS	Ç. Kaspar	6	1	1	8
TOTAL			90	25/200	12/100	127
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.-6.0.	RHE	M. Bıçakçıl	2	-	-	2
1.0.-6.0.	ORT	Ç. Uluçay	2	-	-	2
1.0.-6.0.	PTR	E. Aydog	1	-	-	1
TOTAL			5	-	-	5

PHASE III		COMMITTEE VIII	MUSCULOSKELETAL SYSTEM
I. WEEK			
DAY	HOUR	SUBJECT	LECTURER
12-May-2014	09.00-09.50	<i>Independent study hours</i>	
MONDAY	10.00-10.50	Introduction to Musculoskeletal System	F. Altıntaş
	11.00-11.50	Epidemiology of Musculoskeletal Disorders	S.Karabey
	12.00-12.50	Physical Factors in Workplace and Ergonomics	S.Karabey
	13.00-13.50		
	14.00-14.50	Work Related Musculoskeletal Disorders	S.Karabey
	15.00-15.50	Injury Prevention and Home Accidents, prevention of Disability in Older Person	S.Karabey
	16.00-16.50	Prevention and Risk Factors of Osteoporosis	S.Karabey
	17.00-17.50	<i>Independent study hours</i>	
13-May-2014	09.00-09.50	Trauma	T. Özler
TUESDAY	10.00-10.50	Foot Deformities	Ç. Uluçay
	11.00-11.50	Pathophysiology of Musculoskeletal System Disorders I	M. Koçak
	12.00-12.50	Pathophysiology of Musculoskeletal System Disorders II	M. Koçak
	13.00-13.50		
	14.00-14.50		
	15.00-15.50		
	16.00-16.50	<i>Independent study hours</i>	
	17.00-17.50		
14-May-2014	09.00-09.50	Developmental Disorders of the Skeleton	M. Güven
WEDNESDAY	10.00-10.50	Congenital Dislocation of the Hip	M. Güven
	11.00-11.50	Congenital & Metabolic Diseases of Bone I	F. Özkan
	12.00-12.50	Congenital & Metabolic Diseases of Bone II	F. Özkan
	13.00-13.50		
	14.00-14.50	Monitoring Drug Therapy I	S. Alpan
	15.00-15.50	Monitoring Drug Therapy II	S. Alpan
	16.00-16.50		
	17.00-17.50	<i>Independent study hours</i>	
15-May-2014	09.00-09.50	Osteomyelitis and Septic Arthritis	M. Güven
THURSDAY	10.00-10.50	Upper Extremity Disorders	Ç. Uluçay
	11.00-11.50	Inflammatory Polyarthritis & Rheumatoid Arthritis	M. Bıçakçığıl
	12.00-12.50	Bone and Joint Infections	I.D.Ekici
	13.00-13.50		
	14.00-14.50	Important Drug Interactions I	S. Alpan
	15.00-15.50	Important Drug Interactions II	S. Alpan
	16.00-16.50		
	17.00-17.50	<i>Independent study hours</i>	
16-May-2014	09.00-09.50	Osteoporosis	F. Altıntaş
FRIDAY	10.00-10.50	Degenerative Osteoarthritis	F. Altıntaş
	11.00-11.50	Reproductive Ethics III	E. Vatanoğlu
	12.00-12.50	Reproductive Ethics IV	E. Vatanoğlu
	13.00-13.50		
	14.00-14.50	Degenerative Joint Disease	F. Özkan
	15.00-15.50		
	16.00-16.50	<i>Independent study hours</i>	
	17.00-17.50		

[illegible]

IV. WEEK			
DAY	HOURL	SUBJECT	LECTURER
02-Jun-2014	09.00-09.50	CSL Group IV <i>(Physical examination of the musculoskeletal system)</i>	Ç. Uluçay/ T. Özler
MONDAY	10.00-10.50		
	11.00-11.50		
	12.00-12.50		
	13.00-13.50		
	14.00-14.50		
	15.00-15.50		
	16.00-16.50		
03-Jun-2014	10.00-17.50	OSCE –II EXAM	
TUESDAY			
04-05-Jun-2014	09.00-09.50	Independent study hours	
	10.00-10.50		
	11.00-11.50		
	12.00-12.50		
	13.00-13.50		
	14.00-14.50		
	15.00-15.50		
	16.00-16.50		
06-Jun -2014	10.00-13.00	COMMITTEE EXAM	
FRIDAY			

Contact

Faculty Secretary:

Tel: +90 216 578 05 93

Dean Secretary:

Tel: +90 216 578 05 05-06

Fax: +90 216 578 05 75

Student Affairs:

Tel: 0216 578 06 86

Document Affairs:

Tel: 0216 578 05 23

Coordinator / Co-coordinator:

Yeřim GÜROL, MD Assoc. Prof. (Coordinator) 216 578 00 00 (Ext.3293)

İ. Çağatay ACUNER, MD Assist. Prof. (Co-coordinator) 216 578 00 00 (Ext. 3218)

Ayşegöl ÇINAR KUŞKUCU, MD PhD Assist. Prof. (Co-coordinator) 216 3265819
(Ext.5777)

Address:

Yeditepe University Faculty of Medicine

İnönü Mah., Kayışdağı Caddesi,

26 Ağustos Yerleşimi,

34755 Ataşehir, İstanbul

Web: www.yeditepe.edu.tr

<http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi>

e-mail: tipfakdek@yeditepe.edu.tr



YEDİTEPE UNIVERSITY
FACULTY of MEDICINE

İnönü Mahallesi, Kayışdağı Caddesi,
26 Ağustos Yerleşimi,
34755 Ataşehir, İstanbul

Tel: (+90 216) 578 00 00

www.yeditepe.edu.tr
<http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi>
tipfakdek@yeditepe.edu.tr



YEDİTEPE UNIVERSITY
FACULTY of MEDICINE

İnönü Mah. Kayışdağı Caddesi, 26 Ağustos Yerleşimi,
34755 Ataşehir, İstanbul

+ 90 216 578 00 00

www.yeditepe.edu.tr
<http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi>

tipfakdek@yeditepe.edu.tr